<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Chronic Stress (Thousand Oaks)</journal-id>
<journal-id journal-id-type="iso-abbrev">Chronic Stress (Thousand Oaks)</journal-id>
<journal-id journal-id-type="publisher-id">CSS</journal-id>
<journal-id journal-id-type="hwp">spcss</journal-id>
<journal-title-group>
<journal-title>Chronic Stress</journal-title>
</journal-title-group>
<issn pub-type="epub">2470-5470</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32440589</article-id>
<article-id pub-id-type="pmc">7219929</article-id>
<article-id pub-id-type="doi">10.1177/2470547018818555</article-id>
<article-id pub-id-type="publisher-id">10.1177_2470547018818555</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Overview of the Molecular Steps in Steroidogenesis of the GABAergic
Neurosteroids Allopregnanolone and Pregnanolone</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-3862-7899</contrib-id>
<name>
<surname>Liang</surname>
<given-names>Jennifer J.</given-names>
</name>
<xref ref-type="aff" rid="aff1-2470547018818555">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rasmusson</surname>
<given-names>Ann M.</given-names>
</name>
<xref ref-type="aff" rid="aff1-2470547018818555">1</xref>
<xref ref-type="aff" rid="aff2-2470547018818555">2</xref>
<xref ref-type="aff" rid="aff3-2470547018818555">3</xref>
<xref ref-type="corresp" rid="corresp1-2470547018818555"></xref>
</contrib>
</contrib-group>
<aff id="aff1-2470547018818555"><label>1</label>Boston
University School of Medicine, Boston, MA,
USA</aff>
<aff id="aff2-2470547018818555"><label>2</label>National Center for PTSD, Women’s Health
Science Division, Department of Veterans Affairs, Boston, MA, USA</aff>
<aff id="aff3-2470547018818555"><label>3</label>VA Boston Healthcare System, Boston, MA,
USA</aff>
<author-notes>
<corresp id="corresp1-2470547018818555">Ann M. Rasmusson, MD, 150 S. Huntington
Avenue, MA 02135, USA. Email: <email>ann.rasmusson@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>19</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<season>Jan-Dec</season>
<year>2018</year>
</pub-date>
<volume>2</volume>
<elocation-id>2470547018818555</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>11</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2018</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder content-type="society">SAGE Publications Inc unless otherwise
noted. Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
<license-p>Creative Commons Non Commercial CC BY-NC: This article is distributed
under the terms of the Creative Commons Attribution-NonCommercial 4.0
License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Allopregnanolone and pregnanolone—neurosteroids synthesized from progesterone in
the brain, adrenal gland, ovary and testis—have been implicated in a range of
neuropsychiatric conditions including seizure disorders, post-traumatic stress
disorder, major depression, post-partum depression, pre-menstrual dysphoric
disorder, chronic pain, Parkinson’s disease, Alzheimer’s disease, neurotrauma,
and stroke. Allopregnanolone and pregnanolone equipotently facilitate the
effects of gamma-amino-butyric acid (GABA) at GABA<sub>A</sub> receptors, and
when sulfated, antagonize N-methyl-D-aspartate receptors. They play myriad roles
in neurophysiological homeostasis and adaptation to stress while exerting
anxiolytic, antidepressant, anti-nociceptive, anticonvulsant, anti-inflammatory,
sleep promoting, memory stabilizing, neuroprotective, pro-myelinating, and
neurogenic effects. Given that these neurosteroids are synthesized de novo on
demand, this review details the molecular steps involved in the biochemical
conversion of cholesterol to allopregnanolone and pregnanolone within
steroidogenic cells. Although much is known about the early steps in
neurosteroidogenesis, less is known about transcriptional, translational, and
post-translational processes in allopregnanolone- and pregnanolone-specific
synthesis. Further research to elucidate these mechanisms as well as to optimize
the timing and dose of interventions aimed at altering the synthesis or levels
of these neurosteroids is much needed. This should include the development of
novel therapeutics for the many neuropsychiatric conditions to which
dysregulation of these neurosteroids contributes.</p>
</abstract>
<kwd-group>
<kwd>allopregnanolone</kwd>
<kwd>steroidogenesis</kwd>
<kwd>biosynthesis</kwd>
<kwd>transcriptional regulation</kwd>
<kwd>post-traumatic stress disorder</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January-December 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec1-2470547018818555" sec-type="intro">
<title>Introduction</title>
<p>Allopregnanolone (3α-hydroxy-5α-pregnan-20-one) and pregnanolone
(3α-hydroxy-5β-pregnan-20-one) are neurosteroid metabolites of progesterone that
equipotently and positively modulate the action of gamma-amino-butyric acid (GABA)
at GABA<sub>A</sub> synaptic and extrasynaptic receptors. At nanomolar doses, these
stereoisomers increase the effects of GABA on GABA<sub>A</sub> receptor-mediated
chloride ion influx ∼7 to 10 times, thus markedly enhancing the inhibitory impact of
GABA on neuronal firing.<sup><xref ref-type="bibr" rid="bibr1-2470547018818555">1</xref><xref ref-type="bibr" rid="bibr2-2470547018818555"></xref><xref ref-type="bibr" rid="bibr3-2470547018818555"></xref><xref ref-type="bibr" rid="bibr4-2470547018818555"></xref><xref ref-type="bibr" rid="bibr5-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr6-2470547018818555">6</xref></sup> In contrast, when sulfated,
allopregnanolone and pregnanolone potently antagonize N-methyl-D-aspartate (NMDA)
receptors. In addition, allopregnanolone and pregnanolone play a role in regulating
GABA<sub>A</sub> receptor number and subunit composition, further shaping the
dynamic balance between inhibitory and excitatory neuronal signaling.<sup><xref ref-type="bibr" rid="bibr1-2470547018818555">1</xref></sup></p>
<p>The effects of allopregnanolone and pregnanolone on GABA neurotransmission are
thought to be responsible for their potent antidepressant, anxiolytic,
anti-conflict, anticonvulsant, anti-nociceptive, anesthetic, sleep-promoting, and
memory modulating effects. In addition to these pharmacological effects, these
neurosteroids can suppress inflammation, reduce apoptosis, and promote neurogenesis
and myelination.<sup><xref ref-type="bibr" rid="bibr7-2470547018818555">7</xref><xref ref-type="bibr" rid="bibr8-2470547018818555"></xref><xref ref-type="bibr" rid="bibr9-2470547018818555"></xref><xref ref-type="bibr" rid="bibr10-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr11-2470547018818555">11</xref></sup> At a higher translational
level, such neuroprotective effects manifest as reduced infarct volume and cerebral
edema after cerebral ischemia, delays in neuronal death after traumatic brain injury
or in the context of Niemann-Pick type C disease,<sup><xref ref-type="bibr" rid="bibr2-2470547018818555">2</xref>,<xref ref-type="bibr" rid="bibr12-2470547018818555">12</xref></sup> and lastly as interruption and
reversal of neurodegenerative processes associated with Parkinson’s and Alzheimer’s
disease.<sup><xref ref-type="bibr" rid="bibr13-2470547018818555">13</xref>,<xref ref-type="bibr" rid="bibr14-2470547018818555">14</xref></sup></p>
<p>However, preclinical and clinical research suggests that high as well as low levels
of these neurosteroids may be associated with phenotypically similar
neuropsychiatric disorders.<sup><xref ref-type="bibr" rid="bibr15-2470547018818555">15</xref><xref ref-type="bibr" rid="bibr16-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr17-2470547018818555">17</xref></sup> Even
apparently normal fluctuations in these neurosteroids that induce changes in
GABA<sub>A</sub> receptor subunit composition can be associated with dysphoria
and depressive symptoms during the post-partum period or luteal phase of the
menstrual cycle,<sup><xref ref-type="bibr" rid="bibr18-2470547018818555">18</xref><xref ref-type="bibr" rid="bibr19-2470547018818555"></xref><xref ref-type="bibr" rid="bibr20-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr21-2470547018818555">21</xref></sup> while subnormal increases of
their synthesis in response to stress occur across the menstrual cycle in women with
post-traumatic stress disorder (PTSD),<sup><xref ref-type="bibr" rid="bibr15-2470547018818555">15</xref></sup> which shares many clinical symptoms with premenstrual dysphoric disorder
(PMDD). PTSD is also associated with substantially increased risk for PMDD.<sup><xref ref-type="bibr" rid="bibr9-2470547018818555">9</xref></sup></p>
<p>Given the manifold neurophysiological roles of allopregnanolone and pregnanolone, as
well as their dysregulation in a range of disorders for which treatments warrant
improvement, a review of the complex molecular pathways by which these GABAergic
neurosteroids are synthesized and released may highlight opportunities for the
development of novel precision medicine-based interventions for these disorders.
This review and series of graphics thus were developed from the extant literature
characterizing molecular regulatory factors and key enzymes that interact in
steroidogenic cells from a variety of tissues, including the adrenal gland, brain,
ovary, and testis, to produce allopregnanolone and pregnanolone.</p>
</sec>
<sec id="sec2-2470547018818555">
<title>Overview of Steroid Biosynthesis Leading to Allopregnanolone and
Pregnanolone</title>
<p>Due to their lipophilic nature, steroids such as allopregnanolone and pregnanolone
cannot be stored in steroidogenic cells for later release; thus, nearly all
circulating steroid hormones are synthesized de novo and diffuse out of the cell.
This accounts for the delayed peaking of blood and brain steroid levels in response
to tissue-specific stimulation of neurosteroidogenesis by adrenocorticotropic
hormone (ACTH), luteinizing hormone (LH), or NMDA receptor activation<sup><xref ref-type="bibr" rid="bibr22-2470547018818555">22</xref>,23</sup>—as cells
must activate and increase their steroidogenic capacity on demand. Therefore,
understanding the mechanisms by which allopregnanolone is synthesized is necessary
to understand when and how allopregnanolone and pregnanolone function. The schematic
in <xref ref-type="fig" rid="fig1-2470547018818555">Figure 1</xref> summarizes the
events of allopregnanolone synthesis, which are otherwise described below. Synthesis
of pregnanolone follows similar steps with some differences described under the
section “5β-reductase.” <fig id="fig1-2470547018818555" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Schematic depicting the steps in the steroidogenesis of allopregnanolone
and pregnanolone starting with uptake or synthesis of cholesterol and
ending with allopregnanolone and pregnanolone diffusion out of the cell.
Dashed lines represent movement, whereas solid lines represent a
catalytic reaction. OMM: outer mitochondrial membrane; IMM: inner
mitochondrial membrane; IMS: intermembrane space; 5α-DHP:
5α-dihydroprogesterone; 5β-DHP: 5α-dihydroprogesterone.</p></caption><graphic xlink:href="10.1177_2470547018818555-fig1"></graphic></fig></p>
<sec id="sec3-2470547018818555">
<title>Cholesterol Synthesis and Import</title>
<p>All steroids are synthesized from a common cholesterol precursor. Human
steroidogenic cells source their cholesterol from two processes: uptake of
cholesterol from low density lipoproteins (LDL) via receptor-mediated
endocytosis or de novo cholesterol synthesis.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref></sup></p>
<p>It is thought that the majority of the cholesterol used in steroid biosynthesis
originates from LDLs.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref><xref ref-type="bibr" rid="bibr25-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr26-2470547018818555">26</xref></sup>
Steroidogenic cells activated by trophic hormones upregulate the presence of LDL
receptors on their cellular surface in order to endocytose a greater volume of
LDLs, which are rich in cholesteryl ester.<sup><xref ref-type="bibr" rid="bibr27-2470547018818555">27</xref>,<xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref></sup> These LDLs are broken down
in lysosomes to release the cholesteryl esters, which are further processed by
lysosomal acid lipase (LAL) into cholesterol for use in
steroidogenesis.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr27-2470547018818555">27</xref></sup> Free cholesterol is then transferred from lysosomes via the
soluble glycoprotein Niemann Pick type C 2 (NPC2) to the transmembrane protein
Niemann Pick type C 1 (NPC1), which inserts the cholesterol into the lysosomal
membrane for eventual delivery throughout the cytoplasm.<sup><xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref><xref ref-type="bibr" rid="bibr29-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr30-2470547018818555">30</xref></sup></p>
<p>Alternatively, cells may synthesize cholesterol de novo from three acetyl CoA molecules.<sup><xref ref-type="bibr" rid="bibr31-2470547018818555">31</xref></sup> This reaction, catalyzed by 3-hydroxy-3-methylglutaryl CoA (HMG-CoA)
reductase, represents the committed, rate-limiting step for cholesterol
biosynthesis; activated steroidogenic cells upregulate this enzyme.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref></sup> Although
LDL endocytosis is conventionally thought to be the main source of cholesterol
for steroidogenesis, patients with low LDL levels—such as those with congenital
abetalipoproteinemia—have normal basal cortisol production and normal, or mildly
impaired cortisol secretion in response to ACTH.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr32-2470547018818555">32</xref></sup> This suggests that de novo
cholesterol synthesis may be adequate to provide the precursors for
steroidogenesis under normal conditions; it is not clear whether such
individuals maintain adequate cortisol production during extreme or chronic
stress, conditions under which compensation for impaired steroid production at
the single cell level may be compensated by hyperplasia of the steroidogenic
tissue.</p>
</sec>
<sec id="sec4-2470547018818555">
<title>Intracellular Transport of Cholesterol to Mitochondria</title>
<p>Steroidogenic acute regulatory protein (StAR)-related lipid transfer (START)
domain proteins are related to the steroidogenic acute regulatory protein (StAR,
described below) and contain a domain of 210 conserved amino acids capable of
binding lipids.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr33-2470547018818555">33</xref></sup> Among the 15 proteins in the human START family, StarD4 and
StarD5 are cytosolic proteins that bind cholesterol with high specificity and
affinity in steroidogenic cells.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref></sup> StarD4 has been
co-localized with Acyl-CoA cholesterol acyltransferase (ACAT), which is
responsible for catalyzing the reversible conversion of free cholesterol into
cholesterol ester, suggesting a role for these closely related START domain
proteins in transporting cholesterol throughout the cytosol, including to the
outer mitochondrial membrane (OMM).<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref>,<xref ref-type="bibr" rid="bibr34-2470547018818555">34</xref></sup> In addition, activation of
steroidogenic cells induces changes in mitochondrial morphology that enable a
greater number of close contacts between mitochondria and the endoplasmic
reticulum.<sup><xref ref-type="bibr" rid="bibr35-2470547018818555">35</xref><xref ref-type="bibr" rid="bibr36-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr37-2470547018818555">37</xref></sup> The
resulting domains of the endoplasmic reticulum, called mitochondria-associated
membrane (MAM), are necessary for cholesterol transfer to steroidogenic
mitochondria.<sup><xref ref-type="bibr" rid="bibr35-2470547018818555">35</xref>,<xref ref-type="bibr" rid="bibr38-2470547018818555">38</xref></sup></p>
</sec>
<sec id="sec5-2470547018818555">
<title>Transport of Cholesterol Across the Mitochondrial Membrane</title>
<p>The exact mechanism by which cholesterol is transported from the OMM to the inner
mitochondrial membrane (IMM) is not fully understood, but some of the major
steps and factors involved have been elucidated.</p>
<p>One of the most important proteins involved is StAR, which performs its
cholesterol-transporting role only when anchored to the OMM.<sup><xref ref-type="bibr" rid="bibr35-2470547018818555">35</xref>,<xref ref-type="bibr" rid="bibr39-2470547018818555">39</xref></sup> StAR is
first inserted into the OMM and then internalized into the mitochondrial matrix
where it is degraded by mitochondrial proteases.<sup><xref ref-type="bibr" rid="bibr35-2470547018818555">35</xref>,<xref ref-type="bibr" rid="bibr40-2470547018818555">40</xref>,<xref ref-type="bibr" rid="bibr41-2470547018818555">41</xref></sup> The half-life of a StAR
molecule taking part in the one-way transport from the OMM to the mitochondrial
matrix is around 4 to 5 h.<sup><xref ref-type="bibr" rid="bibr35-2470547018818555">35</xref>,<xref ref-type="bibr" rid="bibr40-2470547018818555">40</xref></sup> Structural analyses have
identified a pocket in StAR capable of binding a single molecule of
cholesterol.<sup><xref ref-type="bibr" rid="bibr35-2470547018818555">35</xref>,<xref ref-type="bibr" rid="bibr42-2470547018818555">42</xref></sup> However, each molecule of StAR supposedly transports
hundreds of molecules of cholesterol, rather than the single cholesterol
molecule suggested by its structural stoichiometry, suggesting yet unknown
mechanisms by which StAR mediates transport of cholesterol.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr43-2470547018818555">43</xref></sup> StAR has
been shown to interact with voltage-dependent anion channels 1 and 2 (VDAC1 and
VDAC2) which are thought to regulate the processing of StAR as it passes from
the OMM to the mitochondrial matrix.<sup><xref ref-type="bibr" rid="bibr44-2470547018818555">44</xref>,<xref ref-type="bibr" rid="bibr45-2470547018818555">45</xref></sup> Another protein in the
σ-receptor family named σ-1 is thought to tether StAR and VDAC2 together to
allow for this interaction in the MAM of the OMM and is essential to the proper
action of StAR.<sup><xref ref-type="bibr" rid="bibr46-2470547018818555">46</xref></sup></p>
<p>Less is known about a controversial protein formerly proposed to play a role in
mitochondrial cholesterol transport, the 18 kDa translocator protein (TSPO)
originally characterized as the peripheral benzodiazepine receptor (PBR).<sup><xref ref-type="bibr" rid="bibr47-2470547018818555">47</xref></sup> TSPO is anchored to the OMM and is estimated to constitute 5% to 10% of
all proteins in the OMM of steroidogenic cells.<sup><xref ref-type="bibr" rid="bibr48-2470547018818555">48</xref><xref ref-type="bibr" rid="bibr49-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr50-2470547018818555">50</xref></sup> TSPO contains a
cholesterol recognition/interaction amino acid consensus (CRAC) domain on its
C-terminus, which extends out into the cytosol.<sup><xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref>,<xref ref-type="bibr" rid="bibr49-2470547018818555">49</xref>,<xref ref-type="bibr" rid="bibr51-2470547018818555">51</xref></sup> TSPO is enriched at
contact sites between the OMM and IMM.<sup><xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref></sup> Although TSPO is initially inserted into the OMM as a monomer, it is
often found in polymeric form, in complex with many other proteins.<sup><xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref>,<xref ref-type="bibr" rid="bibr49-2470547018818555">49</xref>,<xref ref-type="bibr" rid="bibr52-2470547018818555">52</xref></sup></p>
<p>One hypothesis suggests that the aforementioned proteins involved in cholesterol
transport collaborate: StarD4/5 delivers cholesterol to the OMM where StAR is located.<sup><xref ref-type="bibr" rid="bibr53-2470547018818555">53</xref></sup> Subsequently, StAR binds this cholesterol and was thought to transfer it
to TSPO.<sup><xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref></sup> As TSPO is localized to OMM-IMM contact sites, TSPO could move
cholesterol from the OMM to the IMM, a hypothesis established by studies
in vitro as well as a single in vivo embryonic lethal knockout mouse
study.<sup><xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref>,<xref ref-type="bibr" rid="bibr52-2470547018818555">52</xref>,<xref ref-type="bibr" rid="bibr54-2470547018818555">54</xref></sup> However, more recent studies with TSPO knockout mice
demonstrated that loss of TSPO did not affect steroidogenesis or any gross
aspect of development or behavior in comparison to wild-type mice, suggesting
that TSPO does not play an essential role in this process.<sup><xref ref-type="bibr" rid="bibr55-2470547018818555">55</xref><xref ref-type="bibr" rid="bibr56-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr57-2470547018818555">57</xref></sup> However, further research
has demonstrated that a reduction in TSPO does not affect gonadal
steroidogenesis but significantly impairs adrenal steroidogenesis.<sup><xref ref-type="bibr" rid="bibr58-2470547018818555">58</xref></sup> Given its intracellular localization to the OMM, high expression in
steroidogenic tissue, and conflicting results from multiple research groups,
further research will need to be done to elucidate the purpose of TSPO.</p>
<p>Nevertheless, once inserted into the IMM by a now uncertain mechanism, the pools
of cholesterol mobilized for steroidogenesis remain segregated from that for
structural cholesterol<sup><xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref>,<xref ref-type="bibr" rid="bibr59-2470547018818555">59</xref>,<xref ref-type="bibr" rid="bibr60-2470547018818555">60</xref></sup> and undergo the first committed step for steroidogenesis
described below.<sup><xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref>,<xref ref-type="bibr" rid="bibr60-2470547018818555">60</xref></sup></p>
</sec>
<sec id="sec6-2470547018818555">
<title>P450 Side Chain Cleavage</title>
<p>P450 side chain cleavage (P450scc; also known as CYP11A1), located on the IMM,
catalyzes the first committed step of steroidogenesis. P450scc transforms
cholesterol into pregnenolone via a series of three distinct chemical reactions
eventuating in loss of the hydrophobic six-carbon side chain of cholesterol
(hence the name of this enzyme).<sup><xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref>,<xref ref-type="bibr" rid="bibr61-2470547018818555">61</xref></sup> P450scc is so crucial in
committing cells to steroidogenesis that cells are defined as steroidogenic when
they contain this protein.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref></sup></p>
<p>A pair of electrons is required for each of the three chemical reactions
performed by P450scc.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref></sup> P450scc activities thus require two co-factors: ferredoxin reductase,
which receives electrons from NADPH (nicotinamide adenine dinucleotide
phosphate), and ferredoxin, which shuttles electrons from ferredoxin reductase
to P450scc.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref></sup> The first reaction involves 22-hydroxylation of cholesterol
bound to P450scc.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref></sup> Due to the time required for the sequence of electron transport events,
the binding of cholesterol, and the 22-hydroxylation of cholesterol, this first
P450scc reaction constitutes the rate-limiting step in steroidogenesis in which
approximately 20 molecules of cholesterol are processed by each P450scc molecule
per second.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr61-2470547018818555">61</xref></sup> In the second step, the product of the first reaction
undergoes 20-hydroxylation.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref></sup> This is followed by the third step during which the C20-22 bond is
cleaved to produce isocaproaldehyde and pregnenolone (<xref ref-type="fig" rid="fig1-2470547018818555">Figure 1</xref>).<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref></sup></p>
</sec>
<sec id="sec7-2470547018818555">
<title>3β Hydroxysteroid Dehydrogenase Type 1 and Type 2</title>
<p>In the context of allopregnanolone and pregnanolone synthesis, 3β hydroxysteroid
dehydrogenase (3β-HSD) is responsible for transforming pregnenolone into progesterone.<sup><xref ref-type="bibr" rid="bibr62-2470547018818555">62</xref></sup> 3β-HSD exists in two isoforms (3β-HSD1 and 3β-HSD2), which share 93%
homology and a similar quaternary structure except for key residues that confer
different ligand specificities.<sup><xref ref-type="bibr" rid="bibr63-2470547018818555">63</xref></sup> The 3β-HSD2 isoform is thought to be the most relevant for steroid
biosynthesis, as it is expressed in the adrenals, ovaries, and testes—all
traditionally steroidogenic tissues.<sup><xref ref-type="bibr" rid="bibr63-2470547018818555">63</xref></sup> However, the 3β-HSD1 isoform is found in non-steroidogenic tissues<sup><xref ref-type="bibr" rid="bibr63-2470547018818555">63</xref></sup> and therefore may play a role in steroidogenesis in the central nervous
system (CNS). This is important as 3β-HSD1 has a significantly higher affinity
for common substrates, coenzymes, and inhibitors than 3β-HSD2<sup>64</sup> and
thus may have the ability to convert substantially lower concentrations of
pregnenolone to progesterone as might be seen in the CNS. Both isoforms likely
have a similar mechanism of action given the high similarity in structure;
3β-HSD2 is discussed here, as it is more widely studied and has a
well-delineated mechanism of action.</p>
<p>3β-HSD2 is localized to the IMM in close association with P450scc but performs
its catalytic function in the intermembrane space because it requires a low pH
environment to function.<sup><xref ref-type="bibr" rid="bibr63-2470547018818555">63</xref>,<xref ref-type="bibr" rid="bibr65-2470547018818555">65</xref>,<xref ref-type="bibr" rid="bibr66-2470547018818555">66</xref></sup> 3β-HSD2 first performs a dehydrogenation reaction that
converts NAD<sup>+</sup> (nicotinamide adenine dinucleotide) to NADH.<sup><xref ref-type="bibr" rid="bibr62-2470547018818555">62</xref></sup> NADH induces a conformational change in 3β-HSD2, thus creating a
catalytic site for the isomerization reaction that converts pregnenolone to
progesterone.<sup><xref ref-type="bibr" rid="bibr62-2470547018818555">62</xref>,<xref ref-type="bibr" rid="bibr67-2470547018818555">67</xref></sup> The catalytic part of the protein can exist in three forms:
a highly folded form at physiological pH, a partially folded form (molten
globule with a high degree of secondary structure but no defined tertiary
structure) at about pH 4.5, or a completely unfolded form at about pH
3.5.<sup><xref ref-type="bibr" rid="bibr63-2470547018818555">63</xref>,<xref ref-type="bibr" rid="bibr66-2470547018818555">66</xref></sup> 3β-HSD2 is most active when partially unfolded, a state
stabilized by chaperone proteins that prevent 3β-HSD2 aggregation (in the case
of denaturation) and facilitate recycling of the protein back to the less-active
highly folded state during cell quiescence.<sup><xref ref-type="bibr" rid="bibr63-2470547018818555">63</xref>,<xref ref-type="bibr" rid="bibr66-2470547018818555">66</xref>,<xref ref-type="bibr" rid="bibr68-2470547018818555">68</xref></sup> On both the OMM and IMM,
3β-HSD is tightly associated with P450scc and mitochondrial translocase proteins
(Tom22, Tim50, and Tim23) that seem to be necessary for 3β-HSD2
function.<sup><xref ref-type="bibr" rid="bibr63-2470547018818555">63</xref>,<xref ref-type="bibr" rid="bibr65-2470547018818555">65</xref></sup> After synthesis, progesterone crosses the OMM into the
cytosol via passive diffusion.<sup><xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref></sup></p>
</sec>
<sec id="sec8-2470547018818555">
<title>5α-Reductase Type 1 and Type 2 (5α-R2)</title>
<p>5α-Reductase (5α-R) exists in three isoforms.<sup><xref ref-type="bibr" rid="bibr69-2470547018818555">69</xref></sup> Type 1 (SRD5A1 or 5α-R1) is the most abundant isoform in brain, but is
also found in peripheral tissues, including the adrenal gland.<sup><xref ref-type="bibr" rid="bibr70-2470547018818555">70</xref>,<xref ref-type="bibr" rid="bibr71-2470547018818555">71</xref></sup> In the
brain, 5α-R1 has been co-localized with 3α-hydroxysteroid dehydrogenase type 3
(also known as AKR1C2) (3α-HSD3) (see below) in: (a) glutamatergic principal
output neurons of the hippocampus, olfactory bulb, amygdala, thalamus and
cortex, including pyramidal neurons of the prefrontal cortex (PFC) that project
to the amygdala as well as (b) GABAergic principal output neurons such as
cerebellar Purkinje cells, striatal medium spiny neurons, and reticular thalamic
neurons.<sup><xref ref-type="bibr" rid="bibr72-2470547018818555">72</xref>,<xref ref-type="bibr" rid="bibr73-2470547018818555">73</xref></sup> 5α-R2 plays a prominent role in the male reproductive
system, but also has been identified in brain, including the PFC (specifically
pyramidal cells), the pituitary gland (specifically prolactin producing cells),
hypothalamus, and hippocampus.<sup><xref ref-type="bibr" rid="bibr74-2470547018818555">74</xref><xref ref-type="bibr" rid="bibr75-2470547018818555"></xref><xref ref-type="bibr" rid="bibr76-2470547018818555"></xref><xref ref-type="bibr" rid="bibr77-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr78-2470547018818555">78</xref></sup> 5α-R2 is also expressed at
high levels in spinal motor neurons and in the glomerulosa layer of the adrenal gland,<sup><xref ref-type="bibr" rid="bibr79-2470547018818555">79</xref></sup> where it is likely involved in the synthesis of
tetrahydrodeoxycorticosterone (<xref ref-type="fig" rid="fig1-2470547018818555">Figure 1</xref>), another potent GABAergic neuroactive steroid released
into the circulation in response to stress.<sup><xref ref-type="bibr" rid="bibr23-2470547018818555">23</xref></sup> 5α-R3 (SRD5A3) appears to be primarily responsible for mediating the
N-glycosylation of proteins and does not seem to be active in steroidogenesis.<sup><xref ref-type="bibr" rid="bibr69-2470547018818555">69</xref></sup></p>
<p>Differing physiological characteristics of 5α-R1 and 5α-R2 allow these enzymes to
play distinct but overlapping roles in steroid regulation. Both are involved in
catalyzing the reduction of testosterone into its more potent metabolite
5α-dihydrotestosterone (5α-DHT) and progesterone into 5α-dihydroprogesterone
(5α-DHP), the immediate precursor for allopregnanolone.<sup><xref ref-type="bibr" rid="bibr69-2470547018818555">69</xref></sup> 5α-R1 has micromolar affinity for its steroid substrates
(progesterone &gt; testosterone &gt; androstenedione &gt; glucocorticoids) and
is localized to the endoplasmic reticulum.<sup><xref ref-type="bibr" rid="bibr79-2470547018818555">79</xref>,<xref ref-type="bibr" rid="bibr80-2470547018818555">80</xref></sup> There it plays an
important neuroprotective role by catabolizing the large quantities of steroids
produced under conditions of stress<sup><xref ref-type="bibr" rid="bibr81-2470547018818555">81</xref></sup> and certain reproductive phases in females, such as the luteal phase of
the menstrual cycle and pregnancy.<sup><xref ref-type="bibr" rid="bibr77-2470547018818555">77</xref></sup> In male rodents, 5α-R1 activity increases markedly as testosterone levels
decrease<sup>75</sup>—as occurs during intense stress in men.<sup><xref ref-type="bibr" rid="bibr82-2470547018818555">82</xref></sup> In female rodents, testosterone has no effect on 5α-R1 expression in the
PFC, whereas 5α-DHT markedly increases 5α-R1 levels. In contrast, 5α-R2 has
nanomolar affinity for its substrates and thus may be critical in maintaining
adequate resting allopregnanolone levels. In male rodents, 5α-R2 levels fall
markedly when testosterone levels decrease (as occurs during stress) and
normalize when testosterone levels return to normal.<sup><xref ref-type="bibr" rid="bibr75-2470547018818555">75</xref></sup> In contrast, a preliminary unconfirmed report suggests that 5α-R2
expression in hippocampus may increase during acute stress.<sup><xref ref-type="bibr" rid="bibr77-2470547018818555">77</xref></sup> Testosterone and 5α-DHT have lesser effects on 5α-R2 levels in females.<sup><xref ref-type="bibr" rid="bibr76-2470547018818555">76</xref></sup> Of note, potential effects of estradiol on 5α-R levels have not been
reported.</p>
<p>The mechanisms by which 5α-R1 and 5α-R2 reduce their steroid substrates have not
been well elucidated. The hydrophobic nature of 5α-R1 makes it difficult to
solubilize in a form that retains metabolic activity<sup><xref ref-type="bibr" rid="bibr83-2470547018818555">83</xref></sup>; thus, crystallography studies have not been possible. 5α-R1 also lacks
homology with other NADPH/steroid-binding enzymes.<sup><xref ref-type="bibr" rid="bibr84-2470547018818555">84</xref></sup> Studies have, however, determined that the N-terminal part of this
protein binds to steroid substrates, whereas the C-terminal portion containing a
glycine-rich region binds NADPH.<sup><xref ref-type="bibr" rid="bibr83-2470547018818555">83</xref>,<xref ref-type="bibr" rid="bibr84-2470547018818555">84</xref></sup> 5α-R1 works best at pH 5.0
to 8.0 and has a half-life of approximately 20 to 30 h.<sup><xref ref-type="bibr" rid="bibr69-2470547018818555">69</xref></sup> Less is known about the chemical conditions under which 5α-R2 activity is
optimized.</p>
</sec>
<sec id="sec9-2470547018818555">
<title>5β-Reductase</title>
<p>5β-Reductase (5β-R; also known as AKR1D1) is a monomeric cytoplasmic protein that
plays a role in steroid metabolism as well as in cholic acid and
chenodeoxycholic bile acid synthesis.<sup><xref ref-type="bibr" rid="bibr85-2470547018818555">85</xref>,<xref ref-type="bibr" rid="bibr86-2470547018818555">86</xref></sup> It shares homology with
other AKR family members with a similar mechanism of action (e.g., 3α-HSD,
described below).<sup><xref ref-type="bibr" rid="bibr85-2470547018818555">85</xref></sup> Northern blot studies on human tissues demonstrated abundant 5β-R in the
liver in two mRNA isoforms, smaller amounts in the testes in two isoforms, and
trace amounts in all other tissues including the brain in a single isoform.<sup><xref ref-type="bibr" rid="bibr86-2470547018818555">86</xref></sup> This likely reflects a significant role for 5β-R in the inactivation of
steroid hormones, given that two-thirds of these hormones, by mass, undergo
transformation by 5β-R before excretion.<sup><xref ref-type="bibr" rid="bibr87-2470547018818555">87</xref></sup></p>
<p>Among other reactions, 5β-R catalyzes the reduction of progesterone to
5β-dihydroprogesterone (5β-DHP or 5β-pregnane-3-20-dione), the immediate
precursor for pregnanolone and a potent activator of pregnane-X receptor (PXR,
discussed later).<sup><xref ref-type="bibr" rid="bibr88-2470547018818555">88</xref></sup> 5β-R requires NADPH, which induces a conformational change, and allows
for binding of substrate.<sup><xref ref-type="bibr" rid="bibr85-2470547018818555">85</xref></sup> Although the binding and release of NADPH and NADP+ are generally the
slowest steps in 5β-R-mediated reactions, 5β-R efficiency also depends on the
substrate involved.<sup><xref ref-type="bibr" rid="bibr85-2470547018818555">85</xref></sup> Human 5β-R demonstrates high efficiency for the reduction of
progesterone, androstenedione, 17α-hydroxyprogesterone, and testosterone;
reduced efficiency for reduction of aldosterone and corticosterone; and poor
efficiency for reduction of cortisol.<sup><xref ref-type="bibr" rid="bibr86-2470547018818555">86</xref></sup></p>
</sec>
<sec id="sec10-2470547018818555">
<title>3α-Hydroxysteroid Dehydrogenase Type 3</title>
<p>3α-HSD exists in four different isoforms (types 1, 2, 3, and 20a). Type 3
(associated with the AKR1C2 gene) is a cytosolic protein<sup><xref ref-type="bibr" rid="bibr89-2470547018818555">89</xref></sup> found in steroidogenic tissues and the central nervous system.<sup><xref ref-type="bibr" rid="bibr11-2470547018818555">11</xref>,<xref ref-type="bibr" rid="bibr73-2470547018818555">73</xref>,<xref ref-type="bibr" rid="bibr90-2470547018818555">90</xref>,<xref ref-type="bibr" rid="bibr91-2470547018818555">91</xref></sup> Although
3α-HSD3 has been primarily studied with regard to its role in converting 5α-DHT
to 5α-androstane-3α,17β-diol (3α-diol), a very weak androgen and moderately
potent GABAergic neuroactive steroid, it is also responsible for the conversion
of 5α-DHP and 5β-DHP to the potent GABAergic neurosteroid stereoisomers,
allopregnanolone and pregnanolone, respectively.<sup><xref ref-type="bibr" rid="bibr91-2470547018818555">91</xref></sup></p>
<p>Among the 3α-HSD family proteins, 3α-HSD3 has the lowest catalytic efficiency,
but the highest specificity for reducing 3-ketosteroids.<sup><xref ref-type="bibr" rid="bibr91-2470547018818555">91</xref>,<xref ref-type="bibr" rid="bibr92-2470547018818555">92</xref></sup> 3α-HSD3
exists as a monomeric α/β barrel with large loops on one side that confer high
substrate binding specificity due to their unique orientation and a conserved
catalytic tetrad that mediates the reduction reaction.<sup><xref ref-type="bibr" rid="bibr91-2470547018818555">91</xref>,<xref ref-type="bibr" rid="bibr92-2470547018818555">92</xref></sup> 3α-HSD3 binds NADPH before
binding its steroid substrates; it then catalyzes the reduction of the substrate
before releasing the steroid product.<sup><xref ref-type="bibr" rid="bibr91-2470547018818555">91</xref></sup> The rate-limiting step in the 3α-HSD3 conversion of substrate into
product is the dissociation of NADP+ from the enzyme.<sup><xref ref-type="bibr" rid="bibr91-2470547018818555">91</xref>,<xref ref-type="bibr" rid="bibr93-2470547018818555">93</xref></sup></p>
</sec>
<sec id="sec11-2470547018818555">
<title>Diffusion and Receptor Engagement of Allopregnanolone and
Pregnanolone</title>
<p>Once allopregnanolone and pregnanolone have been synthesized, they can bind to
various receptors to mediate their effects. If synthesized in the CNS, they may
travel in an unbound state short distances intraneuronally or through the
interstitial fluid to act in an autocrine or paracrine manner.<sup><xref ref-type="bibr" rid="bibr73-2470547018818555">73</xref></sup> A vascular transport protein has not been identified for the endocrine
action of allopregnanolone, although there are a few likely candidates.
Transcortin, also known as corticosteroid-binding globulin, is synthesized by
the liver and plays a major role in transporting many adrenal steroid products
throughout the body.<sup><xref ref-type="bibr" rid="bibr94-2470547018818555">94</xref>,<xref ref-type="bibr" rid="bibr95-2470547018818555">95</xref></sup> Albumin, the major serum protein, also carries a
significant proportion of steroid hormones and has been shown to bind progesterone.<sup><xref ref-type="bibr" rid="bibr96-2470547018818555">96</xref></sup> A less likely binding carrier is sex hormone-binding globulin, as it has
high binding affinity only for 17β-hydroxysteroid hormones.<sup><xref ref-type="bibr" rid="bibr97-2470547018818555">97</xref></sup></p>
<p>The binding of allopregnanolone to the GABA<sub>A</sub> receptor hypersensitizes
or prolongs the opening time of the chloride ion channel in the presence of
GABA.<sup><xref ref-type="bibr" rid="bibr1-2470547018818555">1</xref>,<xref ref-type="bibr" rid="bibr2-2470547018818555">2</xref></sup> At a high enough concentration, allopregnanolone can also
act as a direct agonist at this receptor.<sup><xref ref-type="bibr" rid="bibr98-2470547018818555">98</xref></sup> Studies have identified allopregnanolone binding sites in the
transmembrane domain of the GABA<sub>A</sub> receptor and suggest that
allopregnanolone may access the receptor from an intracellular
approach.<sup><xref ref-type="bibr" rid="bibr1-2470547018818555">1</xref>,<xref ref-type="bibr" rid="bibr73-2470547018818555">73</xref>,<xref ref-type="bibr" rid="bibr98-2470547018818555">98</xref></sup> Allopregnanolone also binds to membrane progesterone
receptors—putative G-protein-coupled receptors that activate intracellular
second messenger signaling systems—to mediate neuroprotective actions similar to
those mediated by progesterone binding.<sup><xref ref-type="bibr" rid="bibr2-2470547018818555">2</xref>,<xref ref-type="bibr" rid="bibr99-2470547018818555">99</xref></sup> Finally, the nuclear PXR
represents the only non-plasma membrane receptor associated with
allopregnanolone function, as allopregnanolone does not bind to the nuclear
progesterone receptor.<sup><xref ref-type="bibr" rid="bibr2-2470547018818555">2</xref>,<xref ref-type="bibr" rid="bibr100-2470547018818555">100</xref>,<xref ref-type="bibr" rid="bibr101-2470547018818555">101</xref></sup> Other potential signaling partners for
allopregnanolone have yet to be identified.</p>
</sec>
</sec>
<sec id="sec12-2470547018818555">
<title>Common Pathways for Activating Steroidogenic Enzymes</title>
<sec id="sec13-2470547018818555">
<title>Steroidogenic Stimulation by Trophic Hormones</title>
<p>The release of trophic hormones—such as ACTH and LH from the pituitary gland—is
the most prominent and studied stimulus for the activation of steroidogenic
cells in the periphery. The downstream messaging subsequent to ACTH or LH
receptor binding is discussed here as a potential common pathway upon which
other activating signals may converge (<xref ref-type="fig" rid="fig2-2470547018818555">Figure 2</xref>). <fig id="fig2-2470547018818555" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Schematic depicting the activation of a steroidogenic cell with ACTH
or LH. In the adrenal gland, ACTH binds to the GPCR melanocortin 2
receptor (MC2R), whereas in the gonads, LH binds to the GCPR
LH/choriogonadotropin receptor (LHCGR).<sup><xref ref-type="bibr" rid="bibr103-2470547018818555">103</xref></sup> Upon ligand binding to MC2R or LHCGR, these receptors mediate
a signaling cascade through their associated G-protein. The
G<sub>αs</sub> subunit of the cell membrane-bound G-protein
binds guanosine triphosphate (GTP) and dissociates from the
G-protein in order to activate adenylyl cyclase which converts ATP
to 3′,5′-cyclic AMP (cAMP). The increase in cAMP levels activates
protein kinase A (PKA). Meanwhile, the G<sub>βγ</sub> subunit of the
membrane-bound G-protein activates phospholipase C β (PLCβ), which
cleaves diacylglycerols (DAG) from the plasma membrane. The increase
in DAG levels activates PKC. Acute changes secondary to this
activation include the phosphorylation of StAR and TSPO, which
allows for a higher influx of cholesterol across the mitochondrial
membranes allowing for increased steroidogenesis. PKA phosphorylates
and activates cAMP responsive element binding protein (CREB), which
binds to cAMP response elements (CREs) to promote transcription of
several downstream genes involved in neurosteroidogenesis.<sup><xref ref-type="bibr" rid="bibr102-2470547018818555">102</xref></sup> CREs have been identified in the promoters of HMG-CoA
reductase, NPC1, StAR, and P450scc.<sup><xref ref-type="bibr" rid="bibr49-2470547018818555">49</xref>,<xref ref-type="bibr" rid="bibr102-2470547018818555">102</xref>,<xref ref-type="bibr" rid="bibr104-2470547018818555">104</xref>,<xref ref-type="bibr" rid="bibr105-2470547018818555">105</xref></sup> PKC also has been shown to activate two
transcription factors: steroidogenic factor 1 (SF-1) and activating
protein 1 (AP-1).<sup><xref ref-type="bibr" rid="bibr102-2470547018818555">102</xref></sup> SF-1 binding domains have been found in the promoters of
NPC1, StAR, P450scc, and 3β-HSD2.<sup><xref ref-type="bibr" rid="bibr102-2470547018818555">102</xref>,<xref ref-type="bibr" rid="bibr106-2470547018818555">106</xref>,<xref ref-type="bibr" rid="bibr107-2470547018818555">107</xref></sup> AP-1 binding
domains have been found in the promoters of TSPO, P450scc and
3β-HSD2.<sup><xref ref-type="bibr" rid="bibr49-2470547018818555">49</xref>,<xref ref-type="bibr" rid="bibr62-2470547018818555">62</xref>,<xref ref-type="bibr" rid="bibr102-2470547018818555">102</xref></sup> The Nuclear
Receptor 4A (NR4A) family of transcription are involved in
inflammation and have been shown to upregulate StAR and
3β-HSD2.<sup><xref ref-type="bibr" rid="bibr108-2470547018818555">108</xref><xref ref-type="bibr" rid="bibr109-2470547018818555"></xref><xref ref-type="bibr" rid="bibr110-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr111-2470547018818555">111</xref></sup> Long-term changes include activation of
transcription factors which upregulate the transcription of genes
associated with allopregnanolone synthesis. OMM: outer mitochondrial
membrane; IMM: inner mitochondrial membrane; IMS: intermembrane
space; HMG-CoA: 3-hydroxy-3-methylglutaryl CoA; NPC1: Niemann Pick
type C1.</p></caption><graphic xlink:href="10.1177_2470547018818555-fig2"></graphic></fig></p>
<p>The steroidogenic effect of ACTH or LH can be parsed into an acute response that
occurs within seconds and a long-term response that occurs on the order of
minutes to days.<sup><xref ref-type="bibr" rid="bibr102-2470547018818555">102</xref></sup> Acutely, protein kinase A (PKA) phosphorylates StAR at Ser195, which
doubles its enzymatic activity in transporting cholesterol from the OMM to the
IMM.<sup><xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref>,<xref ref-type="bibr" rid="bibr35-2470547018818555">35</xref></sup> TSPO is also a PKA substrate; phosphorylation of TSPO
changes its ligand binding affinity and subsequently increases its
activity.<sup><xref ref-type="bibr" rid="bibr49-2470547018818555">49</xref>,<xref ref-type="bibr" rid="bibr112-2470547018818555">112</xref></sup> Overall, this acute response seems to drive the influx
of cholesterol precursor into the mitochondria—whether by the action of StAR or
TSPO—to saturate catalytic sites available for the first committed step in
steroidogenesis mediated by P450scc. The long-term response to ACTH/LH
activation occurs via PKA or protein kinase C (PKC) phosphorylation of several
transcription factors that regulate steroidogenic enzymes, thereby increasing
the intracellular steroidogenic machinery capacity.</p>
<p>Allopregnanolone and pregnanolone are just two of many end products generated as
steroidogenic cells are activated to higher rates of steroid production.
Although regulation of P450scc and 3β-HSD2 has been fairly well characterized
due to their role in all steroid synthesis pathways, the regulatory mechanisms
of 5α-R, 5β-R, and 3α-HSD3 are less well known. Recent research has shown that
steroidogenic factor 1 (SF-1) regulates 5α-R and 3α-HSD differently: male murine
SF-1 knockout models demonstrate decreased 5α-R mRNA levels and, surprisingly,
increased 3α-HSD mRNA levels.<sup><xref ref-type="bibr" rid="bibr113-2470547018818555">113</xref></sup> A few studies have demonstrated that male rat glial cells respond to
increased cyclic adenosine monophosphate (cAMP) levels by enhancing de novo
increases in 5α-R mRNA levels and activity.<sup><xref ref-type="bibr" rid="bibr114-2470547018818555">114</xref>,<xref ref-type="bibr" rid="bibr115-2470547018818555">115</xref></sup>Similar experiments in
male rodents show that 3α-HSD does not increase in response to increases in cAMP.<sup><xref ref-type="bibr" rid="bibr114-2470547018818555">114</xref></sup> However, these experiments were not conducted in other steroidogenic
tissues or in females. Moreover, the activity of these enzymes is determined not
only by their abundance in the cell but also by the changing redox state of the
cell and the related availability of NADPH, a cofactor required for the
reductive activities of these enzymes.<sup><xref ref-type="bibr" rid="bibr83-2470547018818555">83</xref>,<xref ref-type="bibr" rid="bibr91-2470547018818555">91</xref></sup> The regulatory mechanisms
behind dedicated allopregnanolone production and the means by which production
might change in response to stress (or the many means used by individuals to
cope with stress) are likely to be highly complex and require further
investigation in both sexes. For example, binge alcohol consumption over a month
followed by abrupt alcohol withdrawal in male rodents decreased levels of both
5α-R1 and 3α-HSD in brain.<sup>116</sup>—perhaps by increasing the activity of
NADPH oxidase and reducing availability of NADPH.</p>
</sec>
<sec id="sec14-2470547018818555">
<title>Role of Allopregnanolone in Psychophysiological and Cellular Stress
Responses</title>
<p>Exposing male rodents to intense physical stress, prolonged social isolation, or
drugs that reduce the activity of enzymes in the allopregnanolone synthesis
pathway reduces serum and brain allopregnanolone levels in association with
increases in anxiety and aggression, enhancement of contextual fear
conditioning, decreases in the rate of fear extinction, and deficits in
extinction retention.<sup><xref ref-type="bibr" rid="bibr117-2470547018818555">117</xref><xref ref-type="bibr" rid="bibr118-2470547018818555"></xref><xref ref-type="bibr" rid="bibr119-2470547018818555"></xref><xref ref-type="bibr" rid="bibr120-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr121-2470547018818555">121</xref></sup> In contrast, compounds
that induce neurosteroidogenesis or otherwise increase brain allopregnanolone
levels reduce these negative behavioral outcomes.<sup><xref ref-type="bibr" rid="bibr9-2470547018818555">9</xref>,<xref ref-type="bibr" rid="bibr122-2470547018818555">122</xref></sup> Effects of stress on
allopregnanolone synthesis have been less well studied in female rodents. For
example, while isolation stress appeared to reduce brain allopregnanolone levels
only in ovariectomized, testosterone-replaced female rodents, potential effects
of the diestrus cycle in the normal females were not taken into account,
possibly obscuring the effects of isolation. Other stressor types have not been
investigated in female rodents. In humans, cross-sectional investigations have
demonstrated an inverse relationship between the sum of allopregnanolone and
pregnanolone level in cerebrospinal fluid (CSF) and PTSD severity as well as sex
differences in the enzyme sites at which allopregnanolone synthesis appears to
be blocked in PTSD.<sup><xref ref-type="bibr" rid="bibr15-2470547018818555">15</xref>,<xref ref-type="bibr" rid="bibr123-2470547018818555">123</xref><xref ref-type="bibr" rid="bibr124-2470547018818555"></xref><xref ref-type="bibr" rid="bibr125-2470547018818555"></xref><xref ref-type="bibr" rid="bibr126-2470547018818555"></xref><xref ref-type="bibr" rid="bibr127-2470547018818555"></xref><xref ref-type="bibr" rid="bibr128-2470547018818555"></xref><xref ref-type="bibr" rid="bibr129-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr130-2470547018818555">130</xref></sup> It is unclear whether
deficits in allopregnanolone synthesis precede trauma exposure or result from
trauma exposure or both. Longitudinal studies in humans exposed to severe
stressors such as intense military training exercises or deployment would help
to answer these important questions.</p>
<p>As illustrated in <xref ref-type="fig" rid="fig3-2470547018818555">Figure
3</xref>, several enzymes involved in allopregnanolone biosynthesis, as well
as allopregnanolone itself, also moderate the impact of cellular stressors such
as xenobiotics or reactive oxygen species (ROS) requiring clearance. For
example, TSPO expression increases in response to pro-pathology stressors and
likely protects against apoptosis while preserving cellular mitochondrial
metabolic and signaling capabilities in the face of increasing cellular ROS.<sup><xref ref-type="bibr" rid="bibr49-2470547018818555">49</xref></sup> 3α-HSD3 plays a role in phase II detoxification of polycyclic aromatic
hydrocarbons (PAHs), particulate pollutants released into the air by the burning
of fossil fuels.<sup><xref ref-type="bibr" rid="bibr131-2470547018818555">131</xref><xref ref-type="bibr" rid="bibr132-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr133-2470547018818555">133</xref></sup>Allopregnanolone is one of the many ligands for PXR, a nuclear
receptor that binds promiscuously to both endogenous ligands and xenobiotic
ligands of a hydrophobic nature.<sup><xref ref-type="bibr" rid="bibr100-2470547018818555">100</xref>,<xref ref-type="bibr" rid="bibr137-2470547018818555">137</xref></sup> When bound to a ligand,
PXR binds regulatory elements to the promoter of a variety of genes responsible
for the metabolism and clearance of xenobiotics.<sup><xref ref-type="bibr" rid="bibr137-2470547018818555">137</xref></sup> A well-studied and important effect of PXR is on the CYP3A family of
enzymes responsible for the biotransformation of more than half of all
prescription medications.<sup><xref ref-type="bibr" rid="bibr137-2470547018818555">137</xref></sup> Additionally, PXR drives the expression of phase II detoxification
proteins such as glutathione-S-transferase as well as drug transporters such as
organic anion-transporting polypeptide 2 (OATP2) and multidrug
resistance-associated protein 2 (MRP2), which are responsible for excreting
xenobiotic metabolites into the biliary system.<sup><xref ref-type="bibr" rid="bibr137-2470547018818555">137</xref></sup> Changes in PXR activity—such as those associated with elevations in
allopregnanolone induced by stress, exercise, or the luteal phase of the
menstrual cycle—thus may significantly alter drug metabolism and complicate drug
dosing. PXR also upregulates TSPO, potentially creating positive feedback for
allopregnanolone synthesis—which may be necessary to preserve adequate
allopregnanolone levels in the face of increased PXR-mediated allopregnanolone
metabolism.<sup><xref ref-type="bibr" rid="bibr100-2470547018818555">100</xref>,<xref ref-type="bibr" rid="bibr138-2470547018818555">138</xref></sup> It is not known whether 3α-HSD3 is a target for
PXR-induced upregulation, despite its role as a phase II detoxification protein.
<fig id="fig3-2470547018818555" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Schematic depicting the response of steroidogenic cells to stressors
such as polycyclic aromatic hydrocarbons and ROS. TSPO responds to
stress-related increases in ROS by working with voltage-dependent
anion-selective channel protein 1 (VDAC1) to increase the level of
ROS in the mitochondria, thereby amplifying ROS signaling in the
cell, driving the upregulation of cyclooxygenases, nitric oxide
synthases, lipoxygenases, and NAPDH oxidase.<sup><xref ref-type="bibr" rid="bibr49-2470547018818555">49</xref>,<xref ref-type="bibr" rid="bibr108-2470547018818555">108</xref>,<xref ref-type="bibr" rid="bibr134-2470547018818555">134</xref></sup> It also has been shown to play a role in
blocking ubiquitination of the mitochondria by other factors,
thereby blocking mitophagy.<sup><xref ref-type="bibr" rid="bibr134-2470547018818555">134</xref></sup> Among the regulatory elements that drive expression of the
TSPO gene is an ROS response element in the promoter that binds
specificity protein 1 (SP1), which accumulates in the nucleus upon
activation by ROS. Additionally, a PXR binding site in the TSPO gene
promoter plays a part in the allopregnanolone stress response.<sup><xref ref-type="bibr" rid="bibr100-2470547018818555">100</xref></sup> On the other hand, 3α-HSD3 plays a role in detoxification of
polycyclic aromatic hydrocarbons. PAH first undergoes a phase I
detoxification reaction by the P450 family enzymes (but not P450scc,
which strictly plays a role in steroidogenesis; this family is also
known as the CYP enzymes), to form a dihydrodiol.<sup><xref ref-type="bibr" rid="bibr131-2470547018818555">131</xref><xref ref-type="bibr" rid="bibr132-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr133-2470547018818555">133</xref></sup> 3α-HSD3 then
converts the dihydrodiol into an ortho-quinone, which is further
conjugated to glutathione by a quinone reductase, thus producing a
nontoxic metabolite for excretion from the body.<sup><xref ref-type="bibr" rid="bibr131-2470547018818555">131</xref><xref ref-type="bibr" rid="bibr132-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr133-2470547018818555">133</xref></sup> Both the
dihydrodiol and the ortho-quinone intermediates are capable of
producing ROS and are considered genotoxic.<sup><xref ref-type="bibr" rid="bibr131-2470547018818555">131</xref>,<xref ref-type="bibr" rid="bibr132-2470547018818555">132</xref></sup> However, the
reaction pathway through 3α-HSD3 is the major route for eliminating
PAHs, making the synthesis of these intermediates necessary.<sup><xref ref-type="bibr" rid="bibr135-2470547018818555">135</xref></sup> 3α-HSD3 is regulated by the nuclear factor E2-related factor
2 (Nrf2), which dissociates from its repressor Kelch-like ECH
associated protein 1 (Keap1) upon exposure to increased ROS levels
in the cell.<sup><xref ref-type="bibr" rid="bibr132-2470547018818555">132</xref>,<xref ref-type="bibr" rid="bibr136-2470547018818555">136</xref></sup> Nrf2 binds to the antioxidant response element
(ARE) in the promoter of 3α-HSD3 and upregulates its expression to
meet the detoxification demands of the cell. Both TSPO and
3α-HSD3—enzymes responsible for allopregnanolone synthesis—are
upregulated in response to these stressors, highlighting a role for
allopregnanolone in stress response. OMM: outer mitochondrial
membrane; IMM: inner mitochondrial membrane; IMS: intermembrane
space; 3α-HSD3: 3α-hydroxysteroid dehydrogenase type 3 (aka AKR1C2);
PXR: pregnane X receptor</p></caption><graphic xlink:href="10.1177_2470547018818555-fig3"></graphic></fig></p>
</sec>
</sec>
<sec id="sec15-2470547018818555">
<title>Clinical Implications</title>
<sec id="sec16-2470547018818555">
<title>Phenotypes Associated With Defects Along the Allopregnanolone Synthesis
Pathway</title>
<p>Various defects can arise in the steroidogenic pathway synthesizing
allopregnanolone, many of which are common to steroidogenesis in general. Some
defects are related to specific severe medical disorders that may overshadow
comorbid psychiatric conditions, while others so far have been linked primarily
to psychiatric disorders despite increasing evidence that they contribute to
comorbid medical and substance abuse disorders. Thus, further research will be
important to characterize the full impact of these defects.</p>
<p>At the start of the steroid synthetic process, cells may have deficiencies that
interfere with obtaining, synthesizing, or storing cholesterol precursor.
Defects in LAL result in a range of phenotypes.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr26-2470547018818555">26</xref></sup> Wolman disease, one rare
genetic disorder affecting LAL function, may lead to multi-organ failure and
death in early childhood.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr26-2470547018818555">26</xref></sup> Cholesteryl ester storage
disease is a milder, later-onset form of Wolman disease.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr26-2470547018818555">26</xref></sup> Even so,
Wolman disease has less effect on steroidogenesis than congenital adrenal
hyperplasia (CAH), likely due to the ability of steroidogenic cells to obtain
free cholesterol from other sources.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref></sup> Niemann-Pick disease type C results from the mutation of NPC1, resulting
in an inability to shuttle digested LDL products out of lysosomes.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr27-2470547018818555">27</xref></sup> Lysosomal
glycosphingolipids and cholesterol accumulate to produce a variable phenotype
that generally includes progressive neurodegeneration.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr26-2470547018818555">26</xref>,<xref ref-type="bibr" rid="bibr28-2470547018818555">28</xref></sup> The impact on
allopregnanolone synthesis by statins—which inhibit HMG-CoA reductase and thus
endogenous cholesterol production—has not been thoroughly assessed. It is
possible that patients with pre-treatment synthesis pathway vulnerabilities are
more prone to the negative side effects of these drugs. Cortisol responses to
ACTH were reduced in a small sample of individuals with familial
hypercholesterolemia before and after statin treatment for two months.<sup><xref ref-type="bibr" rid="bibr139-2470547018818555">139</xref></sup> In a larger and longer study, dehydroepiandrosterone sulfate levels in
children and adolescents with familial hypercholesterolemia were similar to
those of their siblings before treatment with a statin, but substantially lower
after 10 years of treatment.<sup><xref ref-type="bibr" rid="bibr140-2470547018818555">140</xref></sup> In a large randomized, placebo-controlled study of otherwise healthy
middle-aged men with hypercholesterolemia, testosterone levels decreased, while
depression, somatization, and self-reported aggression increased after two years
on simvastatin.<sup><xref ref-type="bibr" rid="bibr141-2470547018818555">141</xref></sup> Investigation of the effects of statins on resting and stress-induced
increases in allopregnanolone and other neuroactive steroids are therefore
warranted.</p>
<p>Defects can occur in the trafficking of cholesterol from the OMM to the IMM.
Although controversy exists over whether loss of TSPO results in a significant
clinical phenotype, loss of StAR results in lipoid CAH, a condition
characterized by a nearly complete absence of all circulating steroid hormones,
salt-wasting due to loss of aldosterone, and feminized external genitalia in
patients with an XY genotype.<sup><xref ref-type="bibr" rid="bibr24-2470547018818555">24</xref>,<xref ref-type="bibr" rid="bibr50-2470547018818555">50</xref>,<xref ref-type="bibr" rid="bibr142-2470547018818555">142</xref></sup> Patients with defects in
3β-HSD are also diagnosed with CAH as 3β-HSD is required for synthesis of nearly
all steroidogenic end-products.<sup><xref ref-type="bibr" rid="bibr63-2470547018818555">63</xref></sup> Less severe forms of 3β-HSD deficiency may present as hyperandrogenism in
women, as progesterone precursors are routed into the androgen pathways.<sup><xref ref-type="bibr" rid="bibr142-2470547018818555">142</xref></sup> Due to the accumulation of dehydroepiandrosterone precursors, they may
also present with psychiatric disorders typified by anxiety, depression,
aggression, and increased risk for smoking dependence and other substance abuse disorders.<sup><xref ref-type="bibr" rid="bibr143-2470547018818555">143</xref></sup></p>
<p>Severe mutations in 5α-R2 result in male pseudohermaphroditism wherein patients
with an XY genotype are unable to convert testosterone to 5α-DHT, resulting in
an inability to masculinize the external genitalia.<sup><xref ref-type="bibr" rid="bibr69-2470547018818555">69</xref>,<xref ref-type="bibr" rid="bibr144-2470547018818555">144</xref></sup> Late masculinization of
patients with mutations in 5α-R2 also may result as 5α-R1 activity increases
during puberty.<sup><xref ref-type="bibr" rid="bibr144-2470547018818555">144</xref></sup> Of note, a polymorphism of 5α-R2 has been associated with increased risk
for PTSD in males only.<sup><xref ref-type="bibr" rid="bibr145-2470547018818555">145</xref></sup> 5α-R deficiency in males with PTSD also has been characterized by a
decrease in the ratio of 5α-DHP to progesterone in CSF; the sum of CSF
allopregnanolone and pregnanolone levels were, in turn, strongly and negatively
correlated with PTSD symptoms.<sup><xref ref-type="bibr" rid="bibr10-2470547018818555">10</xref></sup> No mutations of the 5α-R1 gene have been recorded so far in humans,
possibly because dysfunctional phenotypes have gone undetected.<sup><xref ref-type="bibr" rid="bibr69-2470547018818555">69</xref></sup> However, experimental reduction of 5α-R1 expression in male rodents
results in reduced allopregnanolone levels and a behavioral phenotype
characterized by anxiety, resistance to sedation by GABA receptor-active drugs,
aggression, and enhanced contextual fear conditioning resistant to extinction
and extinction retention,<sup>910146</sup> phenomena consistent with PTSD in
humans. 5α-R1/R2 inhibitors (e.g., dutasteride and finasteride) are commonly
used in the treatment of male pattern baldness or benign prostatic hyperplasia,
with a more controversial role in treating prostate cancer.<sup><xref ref-type="bibr" rid="bibr69-2470547018818555">69</xref>,<xref ref-type="bibr" rid="bibr147-2470547018818555">147</xref></sup> One
study suggested that prolonged use of finasteride reduced allopregnanolone
concentrations in CSF.<sup><xref ref-type="bibr" rid="bibr148-2470547018818555">148</xref></sup> Off-target side effects of finasteride (which has submicromolar potency
for 5α-R1, but sub-nanomolar potency for 5α-R2) seen in a subpopulation of males
have included depression, suicidal ideation, reduced sexual interest, increased
aggression, chronic pain and metabolic disturbances—conditions commonly comorbid
with PTSD and major depression.<sup><xref ref-type="bibr" rid="bibr149-2470547018818555">149</xref></sup></p>
<p>Clinically relevant changes in 3α-HSD3 expression have not been well
characterized. Studies have implicated 3α-HSD3 transcription in prostate and
breast cancer.<sup><xref ref-type="bibr" rid="bibr89-2470547018818555">89</xref>,<xref ref-type="bibr" rid="bibr150-2470547018818555">150</xref>,<xref ref-type="bibr" rid="bibr151-2470547018818555">151</xref></sup> Reduced expression of 3α-HSD3 has been associated with hirsutism.<sup><xref ref-type="bibr" rid="bibr152-2470547018818555">152</xref></sup> It also has been associated with Niemann-Pick disease type C, as
allopregnanolone treatment in a mouse model of Niemann-Pick type C delays
symptom onset.<sup><xref ref-type="bibr" rid="bibr12-2470547018818555">12</xref></sup> Female-specific 3α-HSD3 deficiency, suggested by low CSF allopregnanolone
levels and a low ratio of the sum of CSF allopregnanolone and pregnanolone
(measured together due to technical limitations) to 5α-DHP, has been reported in
premenopausal women with PTSD in association with increased negative mood and
PTSD reexperiencing symptoms.<sup><xref ref-type="bibr" rid="bibr125-2470547018818555">125</xref></sup> The mechanisms by which this enzyme may become dysregulated and the range
of clinical conditions resulting from such dysregulation need further
investigation.</p>
</sec>
<sec id="sec17-2470547018818555">
<title>Pharmacological Implications</title>
<p>Pharmacological approaches to altering allopregnanolone availability or
engagement with GABA<sub>A</sub> receptors have primarily targeted
neuropsychiatric pathologies. Small molecule ligands for TSPO have been shown to
suppress anxiety and contextual fear in animal models of PTSD in association
with increasing levels of allopregnanolone.<sup><xref ref-type="bibr" rid="bibr49-2470547018818555">49</xref>,<xref ref-type="bibr" rid="bibr153-2470547018818555">153</xref><xref ref-type="bibr" rid="bibr154-2470547018818555"></xref><xref ref-type="bibr" rid="bibr155-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr156-2470547018818555">156</xref></sup> These ligands (PK11195,
YL-IPA08, and AC-5216) were thought to increase the transfer of cholesterol from
the OMM to IMM by TSPO, thereby driving allopregnanolone synthesis.<sup><xref ref-type="bibr" rid="bibr49-2470547018818555">49</xref>,<xref ref-type="bibr" rid="bibr153-2470547018818555">153</xref>,<xref ref-type="bibr" rid="bibr155-2470547018818555">155</xref>,<xref ref-type="bibr" rid="bibr156-2470547018818555">156</xref></sup> A link
between the administration of these ligands and GABA<sub>A</sub> receptor
activity also has been demonstrated, most likely due to the effects of elevating
allopregnanolone.<sup><xref ref-type="bibr" rid="bibr153-2470547018818555">153</xref>,<xref ref-type="bibr" rid="bibr155-2470547018818555">155</xref>,<xref ref-type="bibr" rid="bibr156-2470547018818555">156</xref></sup> However, given that TSPO
may not play a significant role in steroidogenesis,<sup><xref ref-type="bibr" rid="bibr55-2470547018818555">55</xref><xref ref-type="bibr" rid="bibr56-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr57-2470547018818555">57</xref></sup> the mechanism by which
these ligands act to increase allopregnanolone in mouse models is uncertain.
Given that TSPO is upregulated at areas of brain injury of varied etiologies and
is used as a marker of neuroinflammation,<sup><xref ref-type="bibr" rid="bibr156-2470547018818555">156</xref></sup> it could be speculated that there is some commonality in the pathways of
stress response leading to allopregnanolone synthesis rather than directly
affecting steroidogenesis. The newer knockout mouse model studies seem to
support this approach, with one study demonstrating significantly decreased
capacity for cellular respiration in conditions of increased stress among TSPO
knockout mice in comparison to wild type.<sup><xref ref-type="bibr" rid="bibr57-2470547018818555">57</xref></sup></p>
<p>Selective serotonin reuptake inhibitors increase neurosteroidogenesis at doses
below those that block serotonin reuptake.<sup><xref ref-type="bibr" rid="bibr158-2470547018818555">158</xref></sup> An increase in allopregnanolone levels in the CSF of depressed patients
following fluoxetine or fluvoxamine treatment correlated with decreases in
depressive symptoms.<sup><xref ref-type="bibr" rid="bibr129-2470547018818555">129</xref></sup> Fluoxetine, sertraline, and paroxetine were shown to increase the
affinity of 3α-HSD3 for 5α-DHP in vitro, thereby increasing the rate of
allopregnanolone synthesis from 5α-DHP.<sup><xref ref-type="bibr" rid="bibr158-2470547018818555">158</xref></sup> However, another study suggested that fluoxetine acts in female, but not
male, rats by inhibiting the conversion of allopregnanolone back into 5α-DHP.<sup><xref ref-type="bibr" rid="bibr159-2470547018818555">159</xref></sup> SSRIs also have shown efficacy in some subpopulations with PMDD, a
disorder associated with low allopregnanolone levels in some but not all
studies. However, recent studies have also demonstrated the efficacy of a
GABA<sub>A</sub> receptor modulating steroid antagonist<sup><xref ref-type="bibr" rid="bibr17-2470547018818555">17</xref></sup> in treating PMDD, as well as dutasteride, which prevented luteal phase
increases in plasma allopregnanolone.<sup><xref ref-type="bibr" rid="bibr21-2470547018818555">21</xref></sup> These studies thus highlight the biological heterogeneity of PMDD.</p>
<p>The pharmacological use of allopregnanolone itself has been under investigation
for several neuropsychiatric disorders: status epilepticus, traumatic brain
injury, benign essential tremor, major depression, post-partum depression,
chronic pain, Alzheimer’s disease, autism, and cocaine craving.<sup><xref ref-type="bibr" rid="bibr2-2470547018818555">2</xref>,<xref ref-type="bibr" rid="bibr8-2470547018818555">8</xref>,<xref ref-type="bibr" rid="bibr13-2470547018818555">13</xref>,<xref ref-type="bibr" rid="bibr127-2470547018818555">127</xref>,<xref ref-type="bibr" rid="bibr160-2470547018818555">160</xref><xref ref-type="bibr" rid="bibr161-2470547018818555"></xref><xref ref-type="bibr" rid="bibr162-2470547018818555"></xref><xref ref-type="bibr" rid="bibr163-2470547018818555"></xref><xref ref-type="bibr" rid="bibr164-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr165-2470547018818555">165</xref></sup> Clinical trials of
ganaxolone, a 3β-methylated analog of allopregnanolone with similar GABAergic
properties are underway for treatment of focal epilepsies, female pediatric
epilepsy, and fragile X syndrome.<sup><xref ref-type="bibr" rid="bibr166-2470547018818555">166</xref></sup> Ganaxolone also was recently investigated in PTSD, but trough drug levels
in plasma were low and prevented a conclusive assessment of its efficacy.<sup><xref ref-type="bibr" rid="bibr167-2470547018818555">167</xref></sup> In addition, it is possible that chronic administration of
allopregnanolone or allopregnanolone analogs is not therapeutic in PTSD.</p>
<p>Indeed, support for the therapeutic effects of intermittent (rather than steady
state) administration of allopregnanolone has been demonstrated in rodent models
of Alzheimer’s disease<sup><xref ref-type="bibr" rid="bibr14-2470547018818555">14</xref>,<xref ref-type="bibr" rid="bibr168-2470547018818555">168</xref></sup> as well as in preclinical models of Niemann-Pick type
C disease, traumatic brain injury, diabetic neuropathy, nerve injury, multiple
sclerosis, and Parkinson’s disease.<sup><xref ref-type="bibr" rid="bibr14-2470547018818555">14</xref></sup> In PTSD, too high steady-state allopregnanolone levels would be expected
to suppress reactivity of the sympathetic nervous system and
hypothalamic–pituitary–adrenal axis to novelty or stress,<sup><xref ref-type="bibr" rid="bibr169-2470547018818555">169</xref></sup> thereby interfering with contextual learning and extinction, processes
central to PTSD recovery. Notably, in rodents with experimentally induced
allopregnanolone deficiency and related PTSD-like behaviors (including enhanced
conditioned contextual fear and deficits in contextual fear extinction and
extinction retention), administration of a single high dose of ganaxolone after
the first extinction training session markedly improved the rate of extinction
and extinction retention.<sup><xref ref-type="bibr" rid="bibr163-2470547018818555">163</xref></sup></p>
<p>The enhancement of long-term depression (LTD) and long-term potentiation (LTP)
interference by slowly rising intraneuronal levels of allopregnanolone and
pregnanolone (and perhaps their sulfated metabolites) in response to NMDA
receptor activation<sup><xref ref-type="bibr" rid="bibr22-2470547018818555">22</xref></sup> during extinction learning may enhance consolidation of new learning and
prevent the reconsolidation of non-reinforced fear conditioned associations.<sup><xref ref-type="bibr" rid="bibr120-2470547018818555">120</xref></sup> The gradual development of LTP interference under such conditions is
thought to protect newly modulated synapses from further excitation during
memory consolidation.<sup><xref ref-type="bibr" rid="bibr170-2470547018818555">170</xref></sup> This may apply whether synapses are newly strengthened by LTP (e.g., as
the new safe context is learned under arousing treatment conditions), or
weakened by LTD (e.g., due to non-reinforcement of the previously acquired
association between contextual cues and the previously experienced unconditioned
stimulus). It should be noted, however, that these findings in allopregnanolone
deficient rodents contrast with the studies in wild-type rodents in which acute
allopregnanolone administration has been shown to negatively impact
hippocampus-dependent novel object recognition, spatial learning and memory
consolidation, and contextual fear conditioning.<sup><xref ref-type="bibr" rid="bibr7-2470547018818555">7</xref>,<xref ref-type="bibr" rid="bibr171-2470547018818555">171</xref></sup></p>
<p>Finally, it should be noted that dramatic changes in the target receptor
specificity of these GABAergic neurosteroids can result from small variations in
their structure. The 3β-hydroxylated isomer of allopregnanolone (known as
isopregnanolone, isoallopregnanolone, or epiallopregnanolone) has
GABA<sub>A</sub> receptor subunit selective antagonist effects<sup><xref ref-type="bibr" rid="bibr172-2470547018818555">172</xref>,<xref ref-type="bibr" rid="bibr173-2470547018818555">173</xref></sup> and thus
diminishes some but not all effects of allopregnanolone.<sup><xref ref-type="bibr" rid="bibr173-2470547018818555">173</xref><xref ref-type="bibr" rid="bibr174-2470547018818555"></xref>–<xref ref-type="bibr" rid="bibr175-2470547018818555">175</xref></sup> The 3β-hydroxylated
isomer of pregnanolone (epipregnanolone) also negatively modulates
GABA<sub>A</sub> receptor function and blocks allopregnanolone effects,
while the sulfated metabolites of allopregnanolone, pregnanolone, and
epipregnanolone allosterically antagonize both GABA<sub>A</sub> and NMDA
receptor function.<sup><xref ref-type="bibr" rid="bibr176-2470547018818555">176</xref>,<xref ref-type="bibr" rid="bibr177-2470547018818555">177</xref></sup> In contrast, epiallopregnanolone sulfate facilitates
NMDA receptor function.<sup><xref ref-type="bibr" rid="bibr178-2470547018818555">178</xref></sup></p>
<p>Given the variable receptor effects of these neurosteroid isomers and
metabolites, the relationship of allopregnanolone and pregnanolone to clinical
phenomena of interest may vary depending on the (often unmeasured) presence of
these isomers and metabolites—an important area for future research. In
addition, several of these neurosteroids impact other receptor classes<sup><xref ref-type="bibr" rid="bibr178-2470547018818555">178</xref></sup> so that treatments aimed at altering their synthesis may have
unanticipated off-target effects.</p>
</sec>
</sec>
<sec id="sec18-2470547018818555" sec-type="conclusions">
<title>Conclusion</title>
<p>Allopregnanolone and pregnanolone play significant roles in a range of
neuropsychiatric disorders. As these neurosteroids must be produced de novo in
response to stress or other stimulatory demands, manipulating the pharmacokinetics
of their synthesis constitutes a promising therapeutic approach and requires an
understanding of enzymes involved in their synthesis and upstream molecular
regulation. As noted above, much is known about the initial steps in
steroidogenesis, but less is known about synthetic steps specific to
allopregnanolone and pregnanolone synthesis. Further elucidation of these mechanisms
and exploitation of the steps in the steroidogenic process already detailed may lead
to novel therapeutics for a multitude of conditions. In addition, future
pharmaceutical research should identify subpopulations of individuals for whom
allopregnanolone and pregnanolone synthesis or levels should be augmented versus
constrained and determine whether treatment is best delivered continuously or
episodically. To harness the protective effects of these treatments and to reduce
harm, it may also be necessary to both individualize drug dose and precisely time
dosing relative to disorder-specific neurophysiological processes inherent to
recovery.<sup><xref ref-type="bibr" rid="bibr14-2470547018818555">14</xref>,<xref ref-type="bibr" rid="bibr162-2470547018818555">162</xref>,<xref ref-type="bibr" rid="bibr163-2470547018818555">163</xref></sup></p>
</sec>
</body>
<back>
<sec id="sec19-2470547018818555" sec-type="COI-statement">
<title>Declaration of Conflicting Interests</title>
<p>The author(s) declared the following potential conflicts of interest with respect to
the research, authorship, and/or publication of this article: Within the past three
years, Dr. Rasmusson has served as a paid scientific advisor to Resilience
Therapeutics and Cohen Veterans Bioscience. She has no equity in these
companies.</p>
</sec>
<sec id="sec20-2470547018818555">
<title>Funding</title>
<p>The author(s) received no financial support for the research, authorship, and/or
publication of this article.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-2470547018818555">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carver</surname><given-names>CM</given-names></name><name><surname>Reddy</surname><given-names>DS</given-names></name></person-group>
<article-title>Neurosteroid interactions with synaptic and
extrasynaptic GABAA receptors: Regulation of subunit plasticity, phasic and
tonic inhibition, and neuronal network excitability</article-title>.
<source/>Psychopharmacol
<year>2013</year>; <volume>230</volume>(<issue>2</issue>):
<fpage>151</fpage>–<lpage>188</lpage>.</mixed-citation>
</ref>
<ref id="bibr2-2470547018818555">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guennoun</surname><given-names>R</given-names></name><name><surname>Labombarda</surname><given-names>F</given-names></name><name><surname>Gonzalez Deniselle</surname><given-names>MC</given-names></name><etal>et al.</etal></person-group>
<article-title>Progesterone and allopregnanolone in the central nervous system:
Response to injury and implication for neuroprotection</article-title>.
<source/>J Steroid Biochem Mol Biol
<year>2015</year>; <volume>146</volume>:
<fpage>48</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">25196185</pub-id></mixed-citation>
</ref>
<ref id="bibr3-2470547018818555">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>JA</given-names></name><name><surname>Kirkness</surname><given-names>EF</given-names></name><name><surname>Callachan</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<article-title>Modulation of the GABA<sub>A</sub> receptor by depressant
barbiturates and pregnane steroids</article-title>. <source/>Brit J
Pharmacol
<year>1988</year>; <volume>94</volume>(<issue>4</issue>):
<fpage>1257</fpage>–<lpage>1269</lpage>.<pub-id pub-id-type="pmid">2850060</pub-id></mixed-citation>
</ref>
<ref id="bibr4-2470547018818555">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinna</surname><given-names>G</given-names></name><name><surname>Uzunova</surname><given-names>V</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<article-title>Brain allopregnanolone regulates the potency of the GABAA
receptor agonist muscimol</article-title>. <source/>Neuropharmacol
<year>2000</year>; <volume>39</volume>(<issue>3</issue>):
<fpage>440</fpage>–<lpage>448</lpage>.</mixed-citation>
</ref>
<ref id="bibr5-2470547018818555">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puia</surname><given-names>G</given-names></name><name><surname>Santi</surname><given-names>M</given-names></name><name><surname>Vicini</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>Neurosteroids act on recombinant human GABAA
receptors</article-title>. <source/>Neuron
<year>1990</year>; <volume>4</volume>(<issue>5</issue>):
<fpage>759</fpage>–<lpage>765</lpage>.<pub-id pub-id-type="pmid">2160838</pub-id></mixed-citation>
</ref>
<ref id="bibr6-2470547018818555">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosie</surname><given-names>AM</given-names></name><name><surname>Wilkins</surname><given-names>ME</given-names></name><name><surname>Da Silva</surname><given-names>HMA</given-names></name><name><surname>Smart</surname><given-names>TG</given-names></name></person-group>
<article-title>Endogenous neurosteroids regulate GABAAreceptors
through two discrete transmembrane sites</article-title>.
<source/>Nature
<year>2006</year>; <volume>444</volume>(<issue>7118</issue>):
<fpage>486</fpage>–<lpage>489</lpage>.<pub-id pub-id-type="pmid">17108970</pub-id></mixed-citation>
</ref>
<ref id="bibr7-2470547018818555">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frye</surname><given-names>CA</given-names></name><name><surname>Sturgis</surname><given-names>JD</given-names></name></person-group>
<article-title>Neurosteroids affect spatial/reference, working,
and long-term memory of female rats</article-title>. <source/>Neurobiol Learn
Mem
<year>1995</year>; <volume>64</volume>(<issue>1</issue>):
<fpage>83</fpage>–<lpage>96</lpage>.<pub-id pub-id-type="pmid">7582815</pub-id></mixed-citation>
</ref>
<ref id="bibr8-2470547018818555">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>CO</given-names></name><name><surname>Hoffman</surname><given-names>SW</given-names></name><etal>et al.</etal></person-group>
<article-title>Progesterone and allopregnanolone reduce inflammatory cytokines
after traumatic brain injury</article-title>. <source/>Exp Neurol
<year>2004</year>; <volume>189</volume>(<issue>2</issue>):
<fpage>404</fpage>–<lpage>412</lpage>.<pub-id pub-id-type="pmid">15380490</pub-id></mixed-citation>
</ref>
<ref id="bibr9-2470547018818555">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmusson</surname><given-names>AM</given-names></name><name><surname>Marx</surname><given-names>CE</given-names></name><name><surname>Pineles</surname><given-names>SL</given-names></name><etal>et al.</etal></person-group>
<article-title>Neuroactive steroids and PTSD treatment</article-title>.
<source/>Neurosci Lett
<year>2017</year>; <volume>649</volume>:
<fpage>156</fpage>–<lpage>163</lpage>.<pub-id pub-id-type="pmid">28215878</pub-id></mixed-citation>
</ref>
<ref id="bibr10-2470547018818555">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmusson</surname><given-names>AM</given-names></name><name><surname>Pineles</surname><given-names>SL</given-names></name></person-group>
<article-title>Neurotransmitter, peptide, and steroid hormone
abnormalities in PTSD: biological endophenotypes relevant to
treatment</article-title>. <source/>Curr Psychiatry Rep
<year>2018</year>; <volume>20</volume>(<issue>7</issue>):
<fpage>52</fpage>.<pub-id pub-id-type="pmid">30019147</pub-id></mixed-citation>
</ref>
<ref id="bibr11-2470547018818555">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossetti</surname><given-names>MF</given-names></name><name><surname>Cambiasso</surname><given-names>MJ</given-names></name><name><surname>Holschbach</surname><given-names>MA</given-names></name><etal>et al.</etal></person-group>
<article-title>Estrogens and progestagens: synthesis and action in the
brain</article-title>. <source/>J Neuroendocrinol
<year>2016</year>; <volume>28</volume>:
<fpage>1</fpage>–<lpage>11</lpage>.</mixed-citation>
</ref>
<ref id="bibr12-2470547018818555">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>LD</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Verot</surname><given-names>L</given-names></name><etal>et al.</etal></person-group>
<article-title>Niemann-Pick type C disease involves disrupted
neurosteroidogenesis and responds to allopregnanolone</article-title>.
<source/>Nat Med
<year>2004</year>; <volume>10</volume>(<issue>7</issue>):
<fpage>704</fpage>–<lpage>711</lpage>.<pub-id pub-id-type="pmid">15208706</pub-id></mixed-citation>
</ref>
<ref id="bibr13-2470547018818555">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adeosun</surname><given-names>SO</given-names></name><name><surname>Hou</surname><given-names>X</given-names></name><name><surname>Jiao</surname><given-names>Y</given-names></name><etal>et al.</etal></person-group>
<article-title>Allopregnanolone reinstates tyrosine hydroxylase immunoreactive
neurons and motor performance in an MPTP-lesioned mouse model of Parkinson’s
disease</article-title>. <source/>PLoS One
<year>2012</year>; <volume>7</volume>(<issue>11</issue>):
<fpage>e50040</fpage>.<pub-id pub-id-type="pmid">23209637</pub-id></mixed-citation>
</ref>
<ref id="bibr14-2470547018818555">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinton</surname><given-names>RD</given-names></name></person-group>
<article-title>Neurosteroids as regenerative agents in the
brain: therapeutic implications</article-title>. <source/>Nat Rev
Endocrinol
<year>2013</year>; <volume>9</volume>(<issue>4</issue>):
<fpage>241</fpage>–<lpage>250</lpage>.<pub-id pub-id-type="pmid">23438839</pub-id></mixed-citation>
</ref>
<ref id="bibr15-2470547018818555">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pineles</surname><given-names>SL</given-names></name><name><surname>Nillni</surname><given-names>YI</given-names></name><name><surname>Pinna</surname><given-names>G</given-names></name><etal>et al.</etal></person-group>
<article-title>PTSD in women is associated with a block in conversion of
progesterone to the GABAergic neurosteroids allopregnanolone and
pregnanolone measured in plasma</article-title>.
<source/>Psychoneuroendocrinology
<year>2018</year>; <volume>93</volume>:
<fpage>133</fpage>–<lpage>141</lpage>.<pub-id pub-id-type="pmid">29727810</pub-id></mixed-citation>
</ref>
<ref id="bibr16-2470547018818555">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pineles</surname><given-names>SL</given-names></name><name><surname>Nillni</surname><given-names>YI</given-names></name><name><surname>King</surname><given-names>MW</given-names></name><etal>et al.</etal></person-group>
<article-title>Extinction retention and the menstrual cycle: Different
associations for women with posttraumatic stress disorder</article-title>.
<source/>J Abnorm Psychol
<year>2016</year>; <volume>125</volume>(<issue>3</issue>):
<fpage>349</fpage>–<lpage>355</lpage>.<pub-id pub-id-type="pmid">26866677</pub-id></mixed-citation>
</ref>
<ref id="bibr17-2470547018818555">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bixo</surname><given-names>M</given-names></name><name><surname>Ekberg</surname><given-names>K</given-names></name><name><surname>Poromaa</surname><given-names>IS</given-names></name><etal>et al.</etal></person-group>
<article-title>Treatment of premenstrual dysphoric disorder with the
GABAAreceptor modulating steroid antagonist Sepranolone (UC1010)—a
randomized controlled trial</article-title>.
<source/>Psychoneuroendocrinology
<year>2017</year>; <volume>80</volume>:
<fpage>46</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">28319848</pub-id></mixed-citation>
</ref>
<ref id="bibr18-2470547018818555">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulinello</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>QH</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Smith</surname><given-names>SS</given-names></name></person-group>
<article-title>Short-term exposure to a neuroactive steroid
increases α4 GABAAreceptor subunit levels in association with increased
anxiety in the female rat</article-title>. <source/>Brain Res
<year>2001</year>; <volume>910</volume>(<issue>1–2</issue>):
<fpage>55</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">11489254</pub-id></mixed-citation>
</ref>
<ref id="bibr19-2470547018818555">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulinello</surname><given-names>M</given-names></name></person-group>
<article-title>Anxiogenic effects of neurosteroid exposure: sex
differences and altered GABAA receptor pharmacology in adult
rats</article-title>. <source/>J Pharmacol Exp Ther
<year>2003</year>; <volume>305</volume>(<issue>2</issue>):
<fpage>541</fpage>–<lpage>548</lpage>.<pub-id pub-id-type="pmid">12606703</pub-id></mixed-citation>
</ref>
<ref id="bibr20-2470547018818555">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SS</given-names></name><name><surname>Ruderman</surname><given-names>Y</given-names></name><name><surname>Frye</surname><given-names>C</given-names></name><name><surname>Homanics</surname><given-names>G</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name></person-group>
<article-title>Steroid withdrawal in the mouse results in
anxiogenic effects of 3α,5β-THP: A possible model of premenstrual dysphoric
disorder</article-title>. <source/>Psychopharmacology
<year>2006</year>; <volume>186</volume>(<issue>3</issue>):
<fpage>323</fpage>–<lpage>333</lpage>.<pub-id pub-id-type="pmid">16193334</pub-id></mixed-citation>
</ref>
<ref id="bibr21-2470547018818555">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>PE</given-names></name><name><surname>Rubinow</surname><given-names>DR</given-names></name><name><surname>Nieman</surname><given-names>LK</given-names></name><etal>et al.</etal></person-group>
<article-title>5α-Reductase inhibition prevents the luteal phase increase in
plasma allopregnanolone levels and mitigates symptoms in women with
premenstrual dysphoric disorder</article-title>.
<source/>Neuropsychopharmacology
<year>2016</year>; <volume>41</volume>(<issue>4</issue>):
<fpage>1093</fpage>–<lpage>1102</lpage>.<pub-id pub-id-type="pmid">26272051</pub-id></mixed-citation>
</ref>
<ref id="bibr22-2470547018818555">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izumi</surname><given-names>Y</given-names></name><name><surname>O’dell</surname><given-names>KA</given-names></name><name><surname>Zorumski</surname><given-names>CF</given-names></name></person-group>
<article-title>Metaplastic LTP inhibition after LTD induction
in CA1 hippocampal slices involves NMDA receptor-mediated
neurosteroidogenesis</article-title>. <source/>Physiol Rep
<year>2013</year>; <volume>1</volume>(<issue>5</issue>):
<fpage>1</fpage>–<lpage>10</lpage>.</mixed-citation>
</ref>
<ref id="bibr23-2470547018818555">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purdy</surname><given-names>RH</given-names></name><name><surname>Morrow</surname><given-names>AL</given-names></name><name><surname>Moore</surname><given-names>PH</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name></person-group>
<article-title>Stress-induced elevations of gamma-aminobutyric
acid type A receptor-active steroids in the rat brain</article-title>.
<source/>Proc Natl Acad Sci
<year>1991</year>; <volume>88</volume>(<issue>10</issue>):
<fpage>4553</fpage>–<lpage>4557</lpage>.<pub-id pub-id-type="pmid">1852011</pub-id></mixed-citation>
</ref>
<ref id="bibr24-2470547018818555">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>WL</given-names></name></person-group>
<article-title>Disorders in the initial steps of steroid
hormone synthesis</article-title>. <source/>J Steroid Biochem Mol
Biol
<year>2017</year>; <volume>165</volume>:
<fpage>18</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">26960203</pub-id></mixed-citation>
</ref>
<ref id="bibr25-2470547018818555">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Heikkilä</surname><given-names>P</given-names></name><name><surname>Meng</surname><given-names>QH</given-names></name><name><surname>Kahri</surname><given-names>AI</given-names></name><name><surname>Tikkanen</surname><given-names>MJ</given-names></name><name><surname>Voutilainen</surname><given-names>R</given-names></name></person-group>
<article-title>Expression of low and high density lipoprotein
receptor genes in human adrenals</article-title>. <source/>Eur J
Endocrinol
<year>2000</year>; <volume>142</volume>(<issue>6</issue>):
<fpage>677</fpage>–<lpage>682</lpage>.<pub-id pub-id-type="pmid">10832106</pub-id></mixed-citation>
</ref>
<ref id="bibr26-2470547018818555">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>WL</given-names></name><name><surname>Bose</surname><given-names>HS</given-names></name></person-group>
<article-title>Early steps in steroidogenesis: intracellular
cholesterol trafficking</article-title>. <source/>J Lipid Res
<year>2011</year>; <volume>52</volume>(<issue>12</issue>):
<fpage>2111</fpage>–<lpage>2135</lpage>.<pub-id pub-id-type="pmid">21976778</pub-id></mixed-citation>
</ref>
<ref id="bibr27-2470547018818555">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name></person-group>
<article-title>The LDL receptor</article-title>.
<source/>Arterioscler Thromb Vasc Biol
<year>2009</year>; <volume>29</volume>(<issue>4</issue>):
<fpage>431</fpage>–<lpage>438</lpage>.<pub-id pub-id-type="pmid">19299327</pub-id></mixed-citation>
</ref>
<ref id="bibr28-2470547018818555">
<label>28</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>WL</given-names></name></person-group>
<article-title>Role of mitochondria in
steroidogenesis</article-title>. <source/>Pediatr Adrenal Dis
<year>2010</year>; <volume>20</volume>(<issue>6</issue>):
<fpage>1</fpage>–<lpage>19</lpage>.</mixed-citation>
</ref>
<ref id="bibr29-2470547018818555">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>HJ</given-names></name><name><surname>Abi-Mosleh</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>ML</given-names></name><etal>et al.</etal></person-group>
<article-title>Structure of N-terminal domain of NPC1 reveals distinct
subdomains for binding and transfer of cholesterol</article-title>.
<source/>Cell
<year>2009</year>; <volume>137</volume>(<issue>7</issue>):
<fpage>1213</fpage>–<lpage>1224</lpage>.<pub-id pub-id-type="pmid">19563754</pub-id></mixed-citation>
</ref>
<ref id="bibr30-2470547018818555">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Benoff</surname><given-names>B</given-names></name><name><surname>Liou</surname><given-names>HL</given-names></name><etal>et al.</etal></person-group>
<article-title>Structural basis of sterol binding by NPC2, a lysosomal protein
deficient in Niemann-Pick type C2 disease</article-title>. <source/>J Biol
Chem
<year>2007</year>; <volume>282</volume>(<issue>32</issue>):
<fpage>23525</fpage>–<lpage>23531</lpage>.<pub-id pub-id-type="pmid">17573352</pub-id></mixed-citation>
</ref>
<ref id="bibr31-2470547018818555">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedeke</surname><given-names>L</given-names></name><name><surname>Fernandez-Hernando</surname><given-names>C</given-names></name></person-group>
<article-title>Regulation of cholesterol
homeostasis</article-title>. <source/>Cell Mol Life Sci
<year>2012</year>; <volume>69</volume>(<issue>6</issue>):
<fpage>915</fpage>–<lpage>930</lpage>.<pub-id pub-id-type="pmid">22009455</pub-id></mixed-citation>
</ref>
<ref id="bibr32-2470547018818555">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illingworth</surname><given-names>DR</given-names></name><name><surname>Kenny</surname><given-names>TA</given-names></name><name><surname>Orwoll</surname><given-names>ES</given-names></name></person-group>
<article-title>Adrenal function in heterozygous and homozygous
hypobetalipoproteinemia</article-title>. <source/>J Clin Endocrinol
Metab
<year>1982</year>; <volume>54</volume>(<issue>1</issue>):
<fpage>27</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">7054218</pub-id></mixed-citation>
</ref>
<ref id="bibr33-2470547018818555">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>BJ</given-names></name></person-group>
<article-title>The mammalian START domain protein family in
lipid transport in health and disease</article-title>. <source/>J
Endocrinol
<year>2012</year>; <volume>212</volume>(<issue>3</issue>):
<fpage>257</fpage>–<lpage>275</lpage>.<pub-id pub-id-type="pmid">21965545</pub-id></mixed-citation>
</ref>
<ref id="bibr34-2470547018818555">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Agudo</surname><given-names>D</given-names></name><name><surname>Calderon-Dominguez</surname><given-names>M</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>Subcellular localization and regulation of StarD4 protein in
macrophages and fibroblasts</article-title>. <source/>Biochim Biophys Acta -
Mol Cell Biol Lipids
<year>2011</year>; <volume>1811</volume>(<issue>10</issue>):
<fpage>597</fpage>–<lpage>606</lpage>.</mixed-citation>
</ref>
<ref id="bibr35-2470547018818555">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>AF</given-names></name><name><surname>Orlando</surname><given-names>U</given-names></name><name><surname>Helfenberger</surname><given-names>KE</given-names></name><etal>et al.</etal></person-group>
<article-title>The role of mitochondrial fusion and StAR phosphorylation in the
regulation of StAR activity and steroidogenesis</article-title>. <source/>Mol
Cell Endocrinol
<year>2014</year>; <volume>408</volume>:
<fpage>73</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">25540920</pub-id></mixed-citation>
</ref>
<ref id="bibr36-2470547018818555">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Brito</surname><given-names>OM</given-names></name><name><surname>Scorrano</surname><given-names>L</given-names></name></person-group>
<article-title>Mitofusin-2 regulates mitochondrial and
endoplasmic reticulum morphology and tethering: The role of
Ras</article-title>. <source/>Mitochondrion
<year>2009</year>; <volume>9</volume>(<issue>3</issue>):
<fpage>222</fpage>–<lpage>226</lpage>.<pub-id pub-id-type="pmid">19269351</pub-id></mixed-citation>
</ref>
<ref id="bibr37-2470547018818555">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname><given-names>EA</given-names></name><name><surname>Kliman</surname><given-names>HJ</given-names></name><name><surname>Strauss</surname><given-names>JF</given-names></name><etal>et al.</etal></person-group>
<article-title>Gonadotropins and cyclic adenosine 3′,5′-monophosphate (cAMP)
alter the morphology of cultured human granulosa cells</article-title>.
<source/>Biol Reprod
<year>1986</year>; <volume>34</volume>(<issue>3</issue>):
<fpage>559</fpage>–<lpage>569</lpage>.<pub-id pub-id-type="pmid">3008869</pub-id></mixed-citation>
</ref>
<ref id="bibr38-2470547018818555">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>A</given-names></name><name><surname>Poderoso</surname><given-names>C</given-names></name><name><surname>Cooke</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>Mitochondrial fusion is essential for steroid
biosynthesis</article-title>. <source/>PLoS One
<year>2012</year>; <volume>7</volume>(<issue>9</issue>):
<fpage>1</fpage>–<lpage>12</lpage>.</mixed-citation>
</ref>
<ref id="bibr39-2470547018818555">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>HS</given-names></name><name><surname>Lingappa</surname><given-names>VR</given-names></name><name><surname>Miller</surname><given-names>WL</given-names></name></person-group>
<article-title>Rapid regulation of steroidogenesis by
mitochondrial protein import</article-title>. <source/>Nature
<year>2002</year>; <volume>417</volume>(<issue>6884</issue>):
<fpage>87</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">11986670</pub-id></mixed-citation>
</ref>
<ref id="bibr40-2470547018818555">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granot</surname><given-names>Z</given-names></name><name><surname>Melamed-Book</surname><given-names>N</given-names></name><name><surname>Bahat</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<article-title>Turnover of StAR protein: roles for the proteasome and
mitochondrial proteases</article-title>. <source/>Mol Cell
Endocrinol
<year>2007</year>; <volume>265–266</volume>(<issue>Suppl.</issue>):
<fpage>51</fpage>–<lpage>58</lpage>.</mixed-citation>
</ref>
<ref id="bibr41-2470547018818555">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>WL</given-names></name><name><surname>Strauss</surname><given-names>JF</given-names></name></person-group>
<article-title>Molecular pathology and mechanism of action of
the steroidogenic acute regulatory protein, StAR</article-title>. <source/>J
Steroid Biochem Mol Biol
<year>1999</year>; <volume>69</volume>(<issue>1–6</issue>):
<fpage>131</fpage>–<lpage>141</lpage>.<pub-id pub-id-type="pmid">10418987</pub-id></mixed-citation>
</ref>
<ref id="bibr42-2470547018818555">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsujishita</surname><given-names>Y</given-names></name><name><surname>Hurley</surname><given-names>JH</given-names></name></person-group>
<article-title>Structure and lipid transport mechanism of a
StAR-related domain</article-title>. <source/>Nat Struct Biol
<year>2000</year>; <volume>7</volume>(<issue>5</issue>):
<fpage>408</fpage>–<lpage>414</lpage>.<pub-id pub-id-type="pmid">10802740</pub-id></mixed-citation>
</ref>
<ref id="bibr43-2470547018818555">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artemenko</surname><given-names>IP</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Hales</surname><given-names>DB</given-names></name><etal>et al.</etal></person-group>
<article-title>Mitochondrial processing of newly synthesized steroidogenic acute
regulatory protein (StAR), but not total StAR, mediates cholesterol transfer
to cytochrome P450 side chain cleavage enzyme in adrenal
cells</article-title>. <source/>J Biol Chem
<year>2001</year>; <volume>276</volume>(<issue>49</issue>):
<fpage>46583</fpage>–<lpage>46596</lpage>.<pub-id pub-id-type="pmid">11579102</pub-id></mixed-citation>
</ref>
<ref id="bibr44-2470547018818555">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>M</given-names></name><name><surname>Whittal</surname><given-names>RM</given-names></name><name><surname>Miller</surname><given-names>WL</given-names></name><name><surname>Bose</surname><given-names>HS</given-names></name></person-group>
<article-title>Steroidogenic activity of StAR requires contact
with mitochondrial VDAC1 and phosphate carrier protein</article-title>.
<source/>J Biol Chem
<year>2008</year>; <volume>283</volume>(<issue>14</issue>):
<fpage>8837</fpage>–<lpage>8845</lpage>.<pub-id pub-id-type="pmid">18250166</pub-id></mixed-citation>
</ref>
<ref id="bibr45-2470547018818555">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>M</given-names></name><name><surname>Kaur</surname><given-names>J</given-names></name><name><surname>Pawlak</surname><given-names>KJ</given-names></name><name><surname>Bose</surname><given-names>M</given-names></name><name><surname>Whittal</surname><given-names>RM</given-names></name><name><surname>Bose</surname><given-names>HS</given-names></name></person-group>
<article-title>Mitochondria-associated endoplasmic reticulum
membrane (MAM) regulates steroidogenic activity via steroidogenic acute
regulatory protein (StAR)-voltage-dependent anion channel 2 (VDAC2)
interaction</article-title>. <source/>J Biol Chem
<year>2015</year>; <volume>290</volume>(<issue>5</issue>):
<fpage>2604</fpage>–<lpage>2616</lpage>.<pub-id pub-id-type="pmid">25505173</pub-id></mixed-citation>
</ref>
<ref id="bibr46-2470547018818555">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marriott</surname><given-names>K-SC</given-names></name><name><surname>Prasad</surname><given-names>M</given-names></name><name><surname>Thapliyal</surname><given-names>V</given-names></name><name><surname>Bose</surname><given-names>HS</given-names></name></person-group>
<article-title>Sigma-1 receptor at the mitochondrial-associated
endoplasmic reticulum membrane is responsible for mitochondrial metabolic
regulation</article-title>. <source/>J Pharmacol Exp Ther
<year>2012</year>; <volume>343</volume>(<issue>3</issue>):
<fpage>578</fpage>–<lpage>586</lpage>.<pub-id pub-id-type="pmid">22923735</pub-id></mixed-citation>
</ref>
<ref id="bibr47-2470547018818555">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Midzak</surname><given-names>A</given-names></name><name><surname>Zirkin</surname><given-names>B</given-names></name><name><surname>Papadopoulos</surname><given-names>V</given-names></name></person-group>
<article-title>Translocator protein: pharmacology and
steroidogenesis</article-title>. <source/>Biochem Soc Trans
<year>2015</year>; <volume>43</volume>(<issue>4</issue>):
<fpage>572</fpage>–<lpage>578</lpage>.<pub-id pub-id-type="pmid">26551695</pub-id></mixed-citation>
</ref>
<ref id="bibr48-2470547018818555">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anholt</surname><given-names>RRH</given-names></name><name><surname>Pedersen</surname><given-names>PL</given-names></name><name><surname>De Souza</surname><given-names>EB</given-names></name><name><surname>Snyder</surname><given-names>SH</given-names></name></person-group>
<article-title>The peripheral-type benzodiazepine receptor.
Localization to the mitochondrial outer membrane</article-title>. <source/>J
Biol Chem
<year>1986</year>; <volume>261</volume>(<issue>2</issue>):
<fpage>576</fpage>–<lpage>583</lpage>.<pub-id pub-id-type="pmid">3001071</pub-id></mixed-citation>
</ref>
<ref id="bibr49-2470547018818555">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatliff</surname><given-names>J</given-names></name><name><surname>Campanella</surname><given-names>M</given-names></name></person-group>
<article-title>TSPO: kaleidoscopic 18-kDa amid biochemical
pharmacology, control and targeting of mitochondria</article-title>.
<source/>Biochem J
<year>2016</year>; <volume>473</volume>(<issue>2</issue>):
<fpage>107</fpage>–<lpage>121</lpage>.<pub-id pub-id-type="pmid">26733718</pub-id></mixed-citation>
</ref>
<ref id="bibr50-2470547018818555">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gut</surname><given-names>P</given-names></name><name><surname>Zweckstetter</surname><given-names>M</given-names></name><name><surname>Banati</surname><given-names>RB</given-names></name></person-group>
<article-title>Lost in translocation: the functions of the
18-kD translocator protein</article-title>. <source/>Trends Endocrinol
Metab
<year>2015</year>; <volume>26</volume>(<issue>7</issue>):
<fpage>349</fpage>–<lpage>356</lpage>.<pub-id pub-id-type="pmid">26026242</pub-id></mixed-citation>
</ref>
<ref id="bibr51-2470547018818555">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Garavito</surname><given-names>RM</given-names></name><name><surname>Ferguson-Miller</surname><given-names>S</given-names></name></person-group>
<article-title>Crystal structures of translocator protein
(TSPO) and mutant mimic of a human polymorphism</article-title>.
<source/>Science
<year>2015</year>; <volume>347</volume>:
<fpage>555</fpage>–<lpage>558</lpage>.<pub-id pub-id-type="pmid">25635101</pub-id></mixed-citation>
</ref>
<ref id="bibr52-2470547018818555">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Papadopoulos</surname><given-names>V</given-names></name></person-group>
<article-title>Evolutionary origin of the mitochondrial
cholesterol transport machinery reveals a universal mechanism of steroid
hormone biosynthesis in animals</article-title>. <source/>PLoS One
<year>2013</year>; <volume>8</volume>(<issue>10</issue>):
<fpage>1</fpage>–<lpage>20</lpage>.</mixed-citation>
</ref>
<ref id="bibr53-2470547018818555">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Agudo</surname><given-names>D</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<article-title>Intracellular cholesterol transporter StarD4 binds free
cholesterol and increases cholesteryl ester formation</article-title>.
<source/>J Lipid Res
<year>2008</year>; <volume>49</volume>(<issue>7</issue>):
<fpage>1409</fpage>–<lpage>1419</lpage>.<pub-id pub-id-type="pmid">18403318</pub-id></mixed-citation>
</ref>
<ref id="bibr54-2470547018818555">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papadopoulos</surname><given-names>V</given-names></name><name><surname>Amri</surname><given-names>H</given-names></name><name><surname>Boujrad</surname><given-names>N</given-names></name><etal>et al.</etal></person-group>
<article-title>Peripheral benzodiazepine receptor in cholesterol transport and
steroidogenesis</article-title>. <source/>Steroids
<year>1997</year>; <volume>62</volume>(<issue>1</issue>):
<fpage>21</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="pmid">9029710</pub-id></mixed-citation>
</ref>
<ref id="bibr55-2470547018818555">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morohaku</surname><given-names>K</given-names></name><name><surname>Pelton</surname><given-names>SH</given-names></name><name><surname>Daugherty</surname><given-names>DJ</given-names></name><name><surname>Butler</surname><given-names>WR</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Selvaraj</surname><given-names>V</given-names></name></person-group>
<article-title>Translocator protein/peripheral benzodiazepine
receptor is not required for steroid hormone biosynthesis</article-title>.
<source/>Endocrinology
<year>2014</year>; <volume>155</volume>(<issue>1</issue>):
<fpage>89</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="pmid">24174323</pub-id></mixed-citation>
</ref>
<ref id="bibr56-2470547018818555">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>LN</given-names></name><name><surname>Morohaku</surname><given-names>K</given-names></name><name><surname>Manna</surname><given-names>PR</given-names></name><etal>et al.</etal></person-group>
<article-title>Peripheral benzodiazepine receptor/translocator protein global
knock-out mice are viable with no effects on steroid hormone
biosynthesis</article-title>. <source/>J Biol Chem
<year>2014</year>; <volume>289</volume>(<issue>40</issue>):
<fpage>27444</fpage>–<lpage>27454</lpage>.<pub-id pub-id-type="pmid">24936060</pub-id></mixed-citation>
</ref>
<ref id="bibr57-2470547018818555">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banati</surname><given-names>RB</given-names></name><name><surname>Middleton</surname><given-names>RJ</given-names></name><name><surname>Chan</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>
<article-title>Positron emission tomography and functional characterization of a
complete PBR/TSPO knockout</article-title>. <source/>Nat Commun
<year>2014</year>; <volume>5</volume>:
<fpage>1</fpage>–<lpage>12</lpage>.</mixed-citation>
</ref>
<ref id="bibr58-2470547018818555">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Campioli</surname><given-names>E</given-names></name><name><surname>Midzak</surname><given-names>A</given-names></name><name><surname>Culty</surname><given-names>M</given-names></name><name><surname>Papadopoulos</surname><given-names>V</given-names></name></person-group>
<article-title>Conditional steroidogenic cell-targeted deletion
of TSPO unveils a crucial role in viability and hormone-dependent steroid
formation</article-title>. <source/>Proc Natl Acad Sci
<year>2015</year>; <volume>112</volume>(<issue>23</issue>):
<page-range>7261–2766</page-range>.</mixed-citation>
</ref>
<ref id="bibr59-2470547018818555">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukai</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Yamano</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>
<article-title>Cholesterol accumulation in adrenocortical mitochondria after
ACTH-stimulation</article-title>. <source/>Endocrinol Jpn
<year>1984</year>; <volume>31</volume>(<issue>2</issue>):
<fpage>177</fpage>–<lpage>184</lpage>.<pub-id pub-id-type="pmid">6086296</pub-id></mixed-citation>
</ref>
<ref id="bibr60-2470547018818555">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>VL</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Lambeth</surname><given-names>JD</given-names></name></person-group>
<article-title>Cholesterol pools in rat adrenal mitochondria:
Use of cholesterol oxidase to infer a complex pool
structure</article-title>. <source/>Endocrinology
<year>1992</year>; <volume>130</volume>(<issue>3</issue>):
<fpage>1557</fpage>–<lpage>1563</lpage>.<pub-id pub-id-type="pmid">1537305</pub-id></mixed-citation>
</ref>
<ref id="bibr61-2470547018818555">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuckey</surname><given-names>RC</given-names></name><name><surname>Cameron</surname><given-names>KJ</given-names></name></person-group>
<article-title>Catalytic properties of cytochrome P-450scc
purified from the human placenta: comparison to bovine cytochrome
P-450scc</article-title>. <source/>Biochim Biophys Acta (BBA)/Protein Struct
Mol
<year>1993</year>; <volume>1163</volume>(<issue>2</issue>):
<fpage>185</fpage>–<lpage>194</lpage>.</mixed-citation>
</ref>
<ref id="bibr62-2470547018818555">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simard</surname><given-names>J</given-names></name><name><surname>Ricketts</surname><given-names>ML</given-names></name><name><surname>Gingras</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>Molecular biology of the 3β-hydroxysteroid dehydrogenase/ Δ5-Δ4
isomerase gene family</article-title>. <source/>Endocr Rev
<year>2005</year>; <volume>26</volume>(<issue>4</issue>):
<fpage>525</fpage>–<lpage>582</lpage>.<pub-id pub-id-type="pmid">15632317</pub-id></mixed-citation>
</ref>
<ref id="bibr63-2470547018818555">
<label>63</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>JL</given-names></name><name><surname>Bose</surname><given-names>HS</given-names></name></person-group>
<article-title>Regulation of human 3-beta-hydroxysteroid
dehydrogenase type-2 (3βHSD2) by molecular chaperones and the mitochondrial
environment affects steroidogenesis</article-title>. <source/>J Steroid
Biochem Mol Biol
<year>2015</year>; <volume>151</volume>:
<fpage>74</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">25448736</pub-id></mixed-citation>
</ref>
<ref id="bibr64-2470547018818555">
<label>64</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>JL</given-names></name><name><surname>Boswell</surname><given-names>EL</given-names></name><name><surname>Scaccia</surname><given-names>LA</given-names></name><name><surname>Pletnev</surname><given-names>V</given-names></name><name><surname>Umland</surname><given-names>TC</given-names></name></person-group>
<article-title>Identification of key amino acids responsible
for the substantially higher affinities of human type 1 3β-hydroxysteroid
dehydrogenase/isomerase (3β-HSD1) for substrates, coenzymes and inhibitors
relative to human 3β-HSD2</article-title>. <source/>Bioorg Chem
<year>2005</year>; <volume>280</volume>(<issue>22</issue>):
<fpage>21321</fpage>–<lpage>21328</lpage>.</mixed-citation>
</ref>
<ref id="bibr65-2470547018818555">
<label>65</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlak</surname><given-names>KJ</given-names></name><name><surname>Prasad</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>JL</given-names></name><name><surname>Whittal</surname><given-names>RM</given-names></name><name><surname>Bose</surname><given-names>HS</given-names></name></person-group>
<article-title>Inner mitochondrial translocase Tim50 interacts
with 3β-hydroxysteroid dehydrogenase type 2 to regulate adrenal and gonadal
steroidogenesis</article-title>. <source/>J Biol Chem
<year>2011</year>; <volume>286</volume>(<issue>45</issue>):
<fpage>39130</fpage>–<lpage>39140</lpage>.<pub-id pub-id-type="pmid">21930695</pub-id></mixed-citation>
</ref>
<ref id="bibr66-2470547018818555">
<label>66</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>JL</given-names></name><name><surname>Whittal</surname><given-names>RM</given-names></name><etal>et al.</etal></person-group>
<article-title>Mitochondrial 3β-hydroxysteroid dehydrogenase enzyme activity
requires reversible pH-dependent conformational change at the intermembrane
space</article-title>. <source/>J Biol Chem
<year>2012</year>; <volume>287</volume>(<issue>12</issue>):
<fpage>9534</fpage>–<lpage>9546</lpage>.<pub-id pub-id-type="pmid">22262841</pub-id></mixed-citation>
</ref>
<ref id="bibr67-2470547018818555">
<label>67</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>JL</given-names></name><name><surname>Frieden</surname><given-names>C</given-names></name><name><surname>Nash</surname><given-names>WE</given-names></name><etal>et al.</etal></person-group>
<article-title>An NADH-induced conformational change that mediates the
sequential 3β- hydroxysteroid dehydrogenase/isomerase activities is
supported by affinity labeling and the time-dependent activation of
isomerase</article-title>. <source/>J Biol Chem
<year>1995</year>; <volume>270</volume>(<issue>36</issue>):
<fpage>21003</fpage>–<lpage>21008</lpage>.<pub-id pub-id-type="pmid">7673125</pub-id></mixed-citation>
</ref>
<ref id="bibr68-2470547018818555">
<label>68</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajapaksha</surname><given-names>M</given-names></name><name><surname>Prasad</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>JL</given-names></name><etal>et al.</etal></person-group>
<article-title>Chaperones rejuvenate folding and activity of 3-β hydroxysteroid
dehydrogenase 2</article-title>. <source/>ACS Chemical Biology
<year>2013</year>; <volume>8</volume>:
<fpage>1000</fpage>–<lpage>1008</lpage>.<pub-id pub-id-type="pmid">23485106</pub-id></mixed-citation>
</ref>
<ref id="bibr69-2470547018818555">
<label>69</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traish</surname><given-names>AM</given-names></name></person-group>
<article-title>5α-Reductases in human physiology: an unfolding
story</article-title>. <source/>Endocr Pract
<year>2012</year>; <volume>1</volume>(<issue>1</issue>):
<fpage>1</fpage>–<lpage>38</lpage>.</mixed-citation>
</ref>
<ref id="bibr70-2470547018818555">
<label>70</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Awady</surname><given-names>MK</given-names></name><name><surname>El-Garf</surname><given-names>W</given-names></name><name><surname>El-Houssieny</surname><given-names>L</given-names></name></person-group>
<article-title>Steroid 5alpha reductase mRNA type 1 is
differentially regulated by androgens and glucocorticoids in the rat
liver</article-title>. <source/>Endocr J
<year>2004</year>; <volume>51</volume>(<issue>1</issue>):
<fpage>37</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">15004407</pub-id></mixed-citation>
</ref>
<ref id="bibr71-2470547018818555">
<label>71</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roselli</surname><given-names>CE</given-names></name><name><surname>Finn</surname><given-names>TJ</given-names></name><name><surname>Ronnekleiv-Kelly</surname><given-names>SM</given-names></name><name><surname>Tanchuck</surname><given-names>MA</given-names></name><name><surname>Kaufman</surname><given-names>KR</given-names></name><name><surname>Finn</surname><given-names>DA</given-names></name></person-group>
<article-title>Localization of brain 5α-reductase messenger RNA
in mice selectively bred for high chronic alcohol withdrawal
severity</article-title>. <source/>Alcohol
<year>2011</year>; <volume>45</volume>(<issue>8</issue>):
<fpage>763</fpage>–<lpage>772</lpage>.<pub-id pub-id-type="pmid">21917407</pub-id></mixed-citation>
</ref>
<ref id="bibr72-2470547018818555">
<label>72</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agis-Balboa</surname><given-names>RC</given-names></name><name><surname>Pinna</surname><given-names>G</given-names></name><name><surname>Pibiri</surname><given-names>F</given-names></name><etal>et al.</etal></person-group>
<article-title>Down-regulation of neurosteroid biosynthesis in corticolimbic
circuits mediates social isolation-induced behavior in mice</article-title>.
<source/>Proc Natl Acad Sci
<year>2007</year>; <volume>104</volume>(<issue>47</issue>):
<fpage>18736</fpage>–<lpage>18741</lpage>.<pub-id pub-id-type="pmid">18003893</pub-id></mixed-citation>
</ref>
<ref id="bibr73-2470547018818555">
<label>73</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agís-Balboa</surname><given-names>RC</given-names></name><name><surname>Pinna</surname><given-names>G</given-names></name><name><surname>Zhubi</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<article-title>Characterization of brain neurons that express enzymes mediating
neurosteroid biosynthesis</article-title>. <source/>Proc Natl Acad
Sci
<year>2006</year>; <volume>103</volume>(<issue>39</issue>):
<fpage>14602</fpage>–<lpage>14607</lpage>.<pub-id pub-id-type="pmid">16984997</pub-id></mixed-citation>
</ref>
<ref id="bibr74-2470547018818555">
<label>74</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>JM</given-names></name><name><surname>Gomez-Capilla</surname><given-names>JA</given-names></name><name><surname>Ortega</surname><given-names>E</given-names></name></person-group>
<article-title>Quantitative reverse-transcriptase polymerase
chain reaction assay for mRNA levels of steroid 5α-reductase
isozymes</article-title>. <source/>Analytical Biochem
<year>2002</year>; <volume>307</volume>(<issue>1</issue>):
<fpage>177</fpage>–<lpage>180</lpage>.</mixed-citation>
</ref>
<ref id="bibr75-2470547018818555">
<label>75</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>JM</given-names></name><name><surname>Ortega</surname><given-names>E</given-names></name></person-group>
<article-title>Differential regulation of steroid 5α-reductase
isozymes expression by androgens in the adult rat brain</article-title>.
<source/>FASEB J
<year>2003</year>; <volume>17</volume>(<issue>11</issue>):
<fpage>1428</fpage>–<lpage>1433</lpage>.<pub-id pub-id-type="pmid">12890696</pub-id></mixed-citation>
</ref>
<ref id="bibr76-2470547018818555">
<label>76</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>JM</given-names></name><name><surname>Ortega</surname><given-names>E</given-names></name></person-group>
<article-title>Steroid 5α-reductase isozymes in the adult
female rat brain: central role of dihydrotestosterone</article-title>.
<source/>J Mol Endocrinol
<year>2006</year>; <volume>36</volume>:
<fpage>239</fpage>–<lpage>245</lpage>.<pub-id pub-id-type="pmid">16595696</pub-id></mixed-citation>
</ref>
<ref id="bibr77-2470547018818555">
<label>77</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poletti</surname><given-names>A</given-names></name><name><surname>Coscarella</surname><given-names>A</given-names></name><name><surname>Negri-Cesi</surname><given-names>P</given-names></name><name><surname>Colciago</surname><given-names>A</given-names></name><name><surname>Celotti</surname><given-names>F</given-names></name><name><surname>Martini</surname><given-names>L</given-names></name></person-group>
<article-title>5α-reductase isozymes in the central nervous
system</article-title>. <source/>Steroids
<year>1998</year>; <volume>63</volume>:
<fpage>246</fpage>–<lpage>251</lpage>.<pub-id pub-id-type="pmid">9618779</pub-id></mixed-citation>
</ref>
<ref id="bibr78-2470547018818555">
<label>78</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aumüller</surname><given-names>G</given-names></name><name><surname>Eicheler</surname><given-names>W</given-names></name><name><surname>Renneberg</surname><given-names>H</given-names></name><name><surname>Adermann</surname><given-names>K</given-names></name><name><surname>Vilja</surname><given-names>P</given-names></name><name><surname>Forssmann</surname><given-names>WG</given-names></name></person-group>
<article-title>Immunocytochemical evidence for differential
subcellular localization of 5 alpha-reductase isoenzymes in human
tissues</article-title>. <source/>Acta Anat
<year>1996</year>; <volume>156</volume>(<issue>4</issue>):
<fpage>241</fpage>–<lpage>252</lpage>.<pub-id pub-id-type="pmid">9078395</pub-id></mixed-citation>
</ref>
<ref id="bibr79-2470547018818555">
<label>79</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eicheler</surname><given-names>W</given-names></name><name><surname>Tuohimaa</surname><given-names>P</given-names></name><name><surname>Vilja</surname><given-names>P</given-names></name><name><surname>Adermann</surname><given-names>K</given-names></name><name><surname>Forssmann</surname><given-names>WG</given-names></name><name><surname>Aumüller</surname><given-names>G</given-names></name></person-group>
<article-title>Immunocytochemical localization of human 5
alpha-reductase 2 with polyclonal antibodies in androgen target and
non-target human tissues</article-title>. <source/>J Histochem
Cytochem
<year>1994</year>; <volume>42</volume>:
<fpage>667</fpage>–<lpage>675</lpage>.<pub-id pub-id-type="pmid">8157936</pub-id></mixed-citation>
</ref>
<ref id="bibr80-2470547018818555">
<label>80</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>DW</given-names></name><name><surname>Wilson</surname><given-names>JD</given-names></name></person-group>
<article-title>Steroid 5alpha-reductase: Two genes/two
enzymes</article-title>. <source/>Annu Rev Biochem
<year>1994</year>; <volume>63</volume>:
<fpage>25</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">7979239</pub-id></mixed-citation>
</ref>
<ref id="bibr81-2470547018818555">
<label>81</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Normington</surname><given-names>K</given-names></name><name><surname>Russell</surname><given-names>DW</given-names></name></person-group>
<article-title>Tissue distribution and kinetic characteristics
of rat steroid 5α-reductase isozyme</article-title>. <source/>J Biol
Chem
<year>1992</year>; <volume>267</volume>(<issue>27</issue>):
<fpage>19548</fpage>–<lpage>19554</lpage>.<pub-id pub-id-type="pmid">1527072</pub-id></mixed-citation>
</ref>
<ref id="bibr82-2470547018818555">
<label>82</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>CA</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Mason</surname><given-names>J</given-names></name><etal>et al.</etal></person-group>
<article-title>Hormone profiles in humans experiencing military survival
training</article-title>. <source/>Biol Psychiatry
<year>2000</year>; <volume>47</volume>(<issue>10</issue>):
<fpage>891</fpage>–<lpage>901</lpage>.<pub-id pub-id-type="pmid">10807962</pub-id></mixed-citation>
</ref>
<ref id="bibr83-2470547018818555">
<label>83</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharyya</surname><given-names>AK</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Rajagopalan</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<article-title>Analysis of the steroid binding domain of rat steroid
5α-reductase (isozyme-1) the steroid D-ring binding domain of
5α-reductase</article-title>. <source/>Steroids
<year>1999</year>; <volume>64</volume>(<issue>3</issue>):
<fpage>197</fpage>–<lpage>204</lpage>.<pub-id pub-id-type="pmid">10400380</pub-id></mixed-citation>
</ref>
<ref id="bibr84-2470547018818555">
<label>84</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Bhattacharyya</surname><given-names>AK</given-names></name><name><surname>Taylor</surname><given-names>MF</given-names></name><etal>et al.</etal></person-group>
<article-title>Site-directed mutagenesis studies of the NADPH-binding domain of
rat steroid 5α-reductase (isozyme-1) I: Analysis of aromatic and
hydroxylated amino acid residues</article-title>. <source/>Steroids
<year>1999</year>; <volume>64</volume>(<issue>5</issue>):
<fpage>356</fpage>–<lpage>362</lpage>.<pub-id pub-id-type="pmid">10406485</pub-id></mixed-citation>
</ref>
<ref id="bibr85-2470547018818555">
<label>85</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Penning</surname><given-names>TM</given-names></name></person-group>
<article-title>The rate-determining steps of aldo-keto
reductases (AKRs), a study on human steroid 5β-reductase
(AKR1D1)</article-title>. <source/>Chem Biol Interact
<year>2015</year>; <volume>234</volume>:
<fpage>360</fpage>–<lpage>365</lpage>.<pub-id pub-id-type="pmid">25500266</pub-id></mixed-citation>
</ref>
<ref id="bibr86-2470547018818555">
<label>86</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charbonneau</surname><given-names>A</given-names></name><name><surname>The</surname><given-names>VL</given-names></name></person-group>
<article-title>Genomic organization of a human 5β-reductase and
its pseudogene and substrate selectivity of the expressed
enzyme</article-title>. <source/>Biochim Biophys Acta - Gene Struct
Expr
<year>2001</year>; <volume>1517</volume>(<issue>2</issue>):
<fpage>228</fpage>–<lpage>235</lpage>.</mixed-citation>
</ref>
<ref id="bibr87-2470547018818555">
<label>87</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palermo</surname><given-names>M</given-names></name><name><surname>Marazzi</surname><given-names>MG</given-names></name><name><surname>Hughes</surname><given-names>BA</given-names></name><name><surname>Stewart</surname><given-names>PM</given-names></name><name><surname>Clayton</surname><given-names>PT</given-names></name><name><surname>Shackleton</surname><given-names>CHL</given-names></name></person-group>
<article-title>Human Δ4-3-oxosteroid 5β-reductase (AKR1D1)
deficiency and steroid metabolism</article-title>. <source/>Steroids
<year>2008</year>; <volume>73</volume>(<issue>4</issue>):
<fpage>417</fpage>–<lpage>423</lpage>.<pub-id pub-id-type="pmid">18243262</pub-id></mixed-citation>
</ref>
<ref id="bibr88-2470547018818555">
<label>88</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drury</surname><given-names>JE</given-names></name><name><surname>Di Costanzo</surname><given-names>L</given-names></name><name><surname>Penning</surname><given-names>TM</given-names></name><name><surname>Christianson</surname><given-names>DW</given-names></name></person-group>
<article-title>Inhibition of human steroid 5β-reductase
(AKR1D1) by finasteride and structure of the enzyme-inhibitor
complex</article-title>. <source/>J Biol Chem
<year>2009</year>; <volume>284</volume>(<issue>30</issue>):
<fpage>19786</fpage>–<lpage>19790</lpage>.<pub-id pub-id-type="pmid">19515843</pub-id></mixed-citation>
</ref>
<ref id="bibr89-2470547018818555">
<label>89</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenners</surname><given-names>A</given-names></name><name><surname>Hartmann</surname><given-names>F</given-names></name><name><surname>Jochens</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<article-title>Stromal markers AKR1C1 and AKR1C2 are prognostic factors in
primary human breast cancer</article-title>. <source/>Int J Clin
Oncol
<year>2015</year>; <volume>21</volume>(<issue>3</issue>):
<fpage>548</fpage>–<lpage>556</lpage>.<pub-id pub-id-type="pmid">26573806</pub-id></mixed-citation>
</ref>
<ref id="bibr90-2470547018818555">
<label>90</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dufort</surname><given-names>I</given-names></name><name><surname>Labrie</surname><given-names>F</given-names></name></person-group>
<article-title>Human types 1 and 3 3 alpha-hydroxysteroid
dehydrogenases: differential lability and tissue
distribution</article-title>. <source/>J Clin Endocrinol Metab
<year>2001</year>; <volume>86</volume>(<issue>2</issue>):
<fpage>841</fpage>–<lpage>846</lpage>.<pub-id pub-id-type="pmid">11158055</pub-id></mixed-citation>
</ref>
<ref id="bibr91-2470547018818555">
<label>91</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penning</surname><given-names>TM</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Steckelbroeck</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>Structure-function of human 3α-hydroxysteroid dehydrogenases:
Genes and proteins</article-title>. <source/>Mol Cell Endocrinol
<year>2004</year>; <volume>215</volume>(<issue>1–2</issue>):
<fpage>63</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">15026176</pub-id></mixed-citation>
</ref>
<ref id="bibr92-2470547018818555">
<label>92</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Stayrook</surname><given-names>SE</given-names></name><name><surname>Albert</surname><given-names>RH</given-names></name><etal>et al.</etal></person-group>
<article-title>Crystal structure of human type III 3β-hydroxysteroid
dehydrogenase/bile acid binding protein complexed with NADP+ and
ursodeoxycholate</article-title>. <source/>Biochem
<year>2001</year>; <volume>40</volume>:
<fpage>10161</fpage>–<lpage>10168</lpage>.<pub-id pub-id-type="pmid">11513593</pub-id></mixed-citation>
</ref>
<ref id="bibr93-2470547018818555">
<label>93</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penning</surname><given-names>TM</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Heredia</surname><given-names>VV</given-names></name><etal>et al.</etal></person-group>
<article-title>Structure-function relationships in 3α-hydroxysteroid
dehydrogenases: A comparison of the rat and human isoforms</article-title>.
<source/>J Steroid Biochem Mol Biol
<year>2003</year>; <volume>85</volume>(<issue>2–5</issue>):
<fpage>247</fpage>–<lpage>255</lpage>.<pub-id pub-id-type="pmid">12943710</pub-id></mixed-citation>
</ref>
<ref id="bibr94-2470547018818555">
<label>94</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>JF</given-names></name><name><surname>Nisula</surname><given-names>BC</given-names></name><name><surname>Rodbard</surname><given-names>D</given-names></name></person-group>
<article-title>Transport of steroid hormones: binding of 21
endogenous steroids to both testosterone-binding globulin and
corticosteroid-binding globulin in human plasma</article-title>. <source/>J
Clin Endocrinol Metab
<year>1981</year>; <volume>53</volume>(<issue>1</issue>):
<fpage>58</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="pmid">7195404</pub-id></mixed-citation>
</ref>
<ref id="bibr95-2470547018818555">
<label>95</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammond</surname><given-names>GL</given-names></name></person-group>
<article-title>Plasma steroid-binding proteins: primary
gatekeepers of steroid hormone action</article-title>. <source/>J
Endocrinol
<year>2016</year>; <volume>230</volume>:
<fpage>R13</fpage>–<lpage>R25</lpage>.<pub-id pub-id-type="pmid">27113851</pub-id></mixed-citation>
</ref>
<ref id="bibr96-2470547018818555">
<label>96</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>D</given-names></name><name><surname>Slaunwhite</surname><given-names>WR</given-names></name></person-group>
<article-title>The binding of a synthetic progestin, R5020, to
transcortin and serum albumin</article-title>. <source/>J Clin Endocrinol
Metab
<year>1977</year>; <volume>44</volume>:
<fpage>983</fpage>–<lpage>985</lpage>.<pub-id pub-id-type="pmid">858781</pub-id></mixed-citation>
</ref>
<ref id="bibr97-2470547018818555">
<label>97</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selby</surname><given-names>C</given-names></name></person-group>
<article-title>Sex hormone binding globulin: origin, function
and clinical significance</article-title>. <source/>Ann Clin Biochem An Int J
Biochem Lab Med
<year>1990</year>; <volume>27</volume>(<issue>6</issue>):
<fpage>532</fpage>–<lpage>541</lpage>.</mixed-citation>
</ref>
<ref id="bibr98-2470547018818555">
<label>98</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigel</surname><given-names>E</given-names></name><name><surname>Steinmann</surname><given-names>ME</given-names></name></person-group>
<article-title>Structure, function, and modulation of GABAA
receptors</article-title>. <source/>J Biol Chem
<year>2012</year>; <volume>287</volume>(<issue>48</issue>):
<fpage>40224</fpage>–<lpage>40231</lpage>.<pub-id pub-id-type="pmid">23038269</pub-id></mixed-citation>
</ref>
<ref id="bibr99-2470547018818555">
<label>99</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Pang</surname><given-names>Y</given-names></name></person-group>
<article-title>Membrane progesterone receptors: evidence for
neuroprotective, neurosteroid signaling and neuroendocrine functions in
neuronal cells</article-title>. <source/>Neuroendocrinology
<year>2012</year>; <volume>96</volume>(<issue>2</issue>):
<fpage>162</fpage>–<lpage>171</lpage>.<pub-id pub-id-type="pmid">22687885</pub-id></mixed-citation>
</ref>
<ref id="bibr100-2470547018818555">
<label>100</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frye</surname><given-names>CA</given-names></name><name><surname>Koonce</surname><given-names>CJ</given-names></name><name><surname>Walf</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<article-title>Novel receptor targets for production and action of
allopregnanolone in the central nervous system: a focus on pregnane
xenobiotic receptor</article-title>. <source/>Front Cell Neurosci
<year>2014</year>; <volume>8</volume>: <fpage>106</fpage>.<pub-id pub-id-type="pmid">24782710</pub-id></mixed-citation>
</ref>
<ref id="bibr101-2470547018818555">
<label>101</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamba</surname><given-names>V</given-names></name><name><surname>Yasuda</surname><given-names>K</given-names></name><name><surname>Lamba</surname><given-names>JK</given-names></name><etal>et al.</etal></person-group>
<article-title>PXR (NR1I2): Splice variants in human tissues, including brain,
and identification of neurosteroids and nicotine as PXR
activators</article-title>. <source/>Toxicol Appl Pharmacol
<year>2004</year>; <volume>199</volume>(<issue>3</issue>):
<fpage>251</fpage>–<lpage>265</lpage>.<pub-id pub-id-type="pmid">15364541</pub-id></mixed-citation>
</ref>
<ref id="bibr102-2470547018818555">
<label>102</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggiero</surname><given-names>C</given-names></name><name><surname>Lalli</surname><given-names>E</given-names></name></person-group>
<article-title>Impact of ACTH signaling on transcriptional
regulation of steroidogenic genes</article-title>. <source/>Front
Endocrinol
<year>2016</year>; <volume>7</volume>: <fpage>24</fpage>.</mixed-citation>
</ref>
<ref id="bibr103-2470547018818555">
<label>103</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavoie</surname><given-names>HA</given-names></name><name><surname>King</surname><given-names>SR</given-names></name></person-group>
<article-title>Transcriptional regulation of steroidogenic
genes: STARD1, CYP11A1 and HSD3B</article-title>. <source/>Exp Biol
Med
<year>2009</year>; <volume>234</volume>(<issue>8</issue>):
<fpage>880</fpage>–<lpage>907</lpage>.</mixed-citation>
</ref>
<ref id="bibr104-2470547018818555">
<label>104</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gévry</surname><given-names>NY</given-names></name><name><surname>Lalli</surname><given-names>E</given-names></name><name><surname>Sassone-Corsi</surname><given-names>P</given-names></name><name><surname>Murphy</surname><given-names>BD</given-names></name></person-group>
<article-title>Regulation of Niemann-Pick C1 gene expression by
the 3′5′-cyclic adenosine monophosphate pathway in steroidogenic
cells</article-title>. <source/>Mol Endocrinol
<year>2003</year>; <volume>17</volume>:
<fpage>704</fpage>–<lpage>715</lpage>.<pub-id pub-id-type="pmid">12554781</pub-id></mixed-citation>
</ref>
<ref id="bibr105-2470547018818555">
<label>105</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagor</surname><given-names>WR</given-names></name><name><surname>De Groh</surname><given-names>ED</given-names></name><name><surname>Ness</surname><given-names>GC</given-names></name></person-group>
<article-title>Diabetes alters the occupancy of the hepatic
3-hydroxy-3-methylglutaryl-CoA reductase promoter</article-title>. <source/>J
Biol Chem
<year>2005</year>; <volume>280</volume>(<issue>44</issue>):
<fpage>36601</fpage>–<lpage>36608</lpage>.<pub-id pub-id-type="pmid">16127173</pub-id></mixed-citation>
</ref>
<ref id="bibr106-2470547018818555">
<label>106</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoivik</surname><given-names>EA</given-names></name><name><surname>Lewis</surname><given-names>AE</given-names></name><name><surname>Aumo</surname><given-names>L</given-names></name><name><surname>Bakke</surname><given-names>M</given-names></name></person-group>
<article-title>Molecular aspects of steroidogenic factor 1
(SF-1)</article-title>. <source/>Mol Cell Endocrinol
<year>2010</year>; <volume>315</volume>(<issue>1–2</issue>):
<fpage>27</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">19616058</pub-id></mixed-citation>
</ref>
<ref id="bibr107-2470547018818555">
<label>107</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>MK</given-names></name><name><surname>Ekstr</surname><given-names>B</given-names></name><name><surname>Zamaratskaia</surname><given-names>G</given-names></name></person-group>
<article-title>Regulation of 3β-hydroxysteroid
dehydrogenase/Δ5-Δ4 isomerase: A review</article-title>. <source/>Int J Mol
Sci
<year>2013</year>; <volume>14</volume>(<issue>9</issue>):
<fpage>17926</fpage>–<lpage>17942</lpage>.<pub-id pub-id-type="pmid">24002028</pub-id></mixed-citation>
</ref>
<ref id="bibr108-2470547018818555">
<label>108</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassett</surname><given-names>MH</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Sasano</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<article-title>The orphan nuclear receptor NGFIB regulates transcription of
3a-hydroxysteroid dehydrogenase: Implications for the control of adrenal
functional zonation</article-title>. <source/>J Biol Chem
<year>2004</year>; <volume>279</volume>(<issue>36</issue>):
<fpage>37622</fpage>–<lpage>37630</lpage>.<pub-id pub-id-type="pmid">15208301</pub-id></mixed-citation>
</ref>
<ref id="bibr109-2470547018818555">
<label>109</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurakula</surname><given-names>K</given-names></name><name><surname>Koenis</surname><given-names>DS</given-names></name><name><surname>van Tiel</surname><given-names>CM</given-names></name><name><surname>de Vries</surname><given-names>CJM</given-names></name></person-group>
<article-title>NR4A nuclear receptors are orphans but not
lonesome</article-title>. <source/>Biochim Biophys Acta
<year>2014</year>; <volume>1843</volume>(<issue>11</issue>):
<fpage>2543</fpage>–<lpage>2555</lpage>.<pub-id pub-id-type="pmid">24975497</pub-id></mixed-citation>
</ref>
<ref id="bibr110-2470547018818555">
<label>110</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sewer</surname><given-names>MB</given-names></name><name><surname>Dammer</surname><given-names>EB</given-names></name><name><surname>Jagarlapudi</surname><given-names>S</given-names></name></person-group>
<article-title>Transcriptional regulation of adrenocortical
steroidogenic gene expression</article-title>. <source/>Drug Metab
Rev
<year>2007</year>; <volume>39</volume>(<issue>2–3</issue>):
<fpage>371</fpage>–<lpage>388</lpage>.<pub-id pub-id-type="pmid">17786627</pub-id></mixed-citation>
</ref>
<ref id="bibr111-2470547018818555">
<label>111</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volakakis</surname><given-names>N</given-names></name><name><surname>Kadkhodaei</surname><given-names>B</given-names></name><name><surname>Joodmardi</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<article-title>NR4A orphan nuclear receptors as mediators of CREB-dependent
neuroprotection</article-title>. <source/>Proc Natl Acad Sci
<year>2010</year>; <volume>107</volume>(<issue>27</issue>):
<fpage>12317</fpage>–<lpage>12322</lpage>.<pub-id pub-id-type="pmid">20566846</pub-id></mixed-citation>
</ref>
<ref id="bibr112-2470547018818555">
<label>112</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whalin</surname><given-names>ME</given-names></name><name><surname>Boujrad</surname><given-names>N</given-names></name><name><surname>Papadopoulos</surname><given-names>V</given-names></name><name><surname>Krueger</surname><given-names>KE</given-names></name></person-group>
<article-title>Studies on the phosphorylation of the 18 kDa
mitochondrial benzodiazepine receptor protein</article-title>. <source/>J
Recept Res
<year>1994</year>; <volume>14</volume>:
<fpage>217</fpage>–<lpage>228</lpage>.<pub-id pub-id-type="pmid">8083866</pub-id></mixed-citation>
</ref>
<ref id="bibr113-2470547018818555">
<label>113</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spanic</surname><given-names>T</given-names></name><name><surname>Fabjan</surname><given-names>T</given-names></name><name><surname>Majdic</surname><given-names>G</given-names></name></person-group>
<article-title>Expression levels of mRNA for neurosteroidogenic
enzymes 17β-HSD, 5α-reductase, 3α-HSD and cytochrome P450 aromatase in the
fetal wild type and SF-1 knockout mouse brain</article-title>.
<source/>Endocr Res
<year>2015</year>; <volume>40</volume>(<issue>1</issue>):
<fpage>44</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">25111584</pub-id></mixed-citation>
</ref>
<ref id="bibr114-2470547018818555">
<label>114</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melcangi</surname><given-names>RC</given-names></name><name><surname>Celotti</surname><given-names>F</given-names></name><name><surname>Castano</surname><given-names>P</given-names></name><name><surname>Martini</surname><given-names>L</given-names></name></person-group>
<article-title>Intracellular signalling systems controlling the
5 alpha-reductase in glial cell cultures</article-title>. <source/>Brain
Res
<year>1992</year>; <volume>585</volume>(<issue>1–2</issue>):
<fpage>411</fpage>–<lpage>415</lpage>.<pub-id pub-id-type="pmid">1511328</pub-id></mixed-citation>
</ref>
<ref id="bibr115-2470547018818555">
<label>115</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>K</given-names></name><name><surname>Arimochi</surname><given-names>H</given-names></name><name><surname>Tsuruo</surname><given-names>Y</given-names></name></person-group>
<article-title>Adrenergic activation of steroid 5α-reductase
gene expression in rat C6 glioma cells: involvement of cyclic AMP/protein
kinase A-mediated signaling pathway</article-title>. <source/>J Mol
Neurosci
<year>2004</year>; <volume>22</volume>:
<fpage>205</fpage>–<lpage>212</lpage>.<pub-id pub-id-type="pmid">14997014</pub-id></mixed-citation>
</ref>
<ref id="bibr116-2470547018818555">
<label>116</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cagetti</surname><given-names>E</given-names></name><name><surname>Pinna</surname><given-names>G</given-names></name><name><surname>Guidotti</surname><given-names>A</given-names></name><name><surname>Baicy</surname><given-names>K</given-names></name><name><surname>Olsen</surname><given-names>RW</given-names></name></person-group>
<article-title>Chronic intermittent ethanol (CIE)
administration in rats decreases levels of neurosteroids in hippocampus,
accompanied by altered behavioral responses to neurosteroids and memory
function</article-title>. <source/>Neuropharmacology
<year>2004</year>; <volume>46</volume>(<issue>4</issue>):
<fpage>570</fpage>–<lpage>579</lpage>.<pub-id pub-id-type="pmid">14975681</pub-id></mixed-citation>
</ref>
<ref id="bibr117-2470547018818555">
<label>117</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagaya</surname><given-names>N</given-names></name><name><surname>Acca</surname><given-names>GM</given-names></name><name><surname>Maren</surname><given-names>S</given-names></name></person-group>
<article-title>Allopregnanolone in the bed nucleus of the stria
terminalis modulates contextual fear in rats</article-title>. <source/>Front
Behav Neurosci
<year>2015</year>; <volume>9</volume>:
<fpage>1</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="pmid">25653603</pub-id></mixed-citation>
</ref>
<ref id="bibr118-2470547018818555">
<label>118</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pibiri</surname><given-names>F</given-names></name><name><surname>Nelson</surname><given-names>M</given-names></name><name><surname>Guidotti</surname><given-names>A</given-names></name><name><surname>Costa</surname><given-names>E</given-names></name><name><surname>Pinna</surname><given-names>G</given-names></name></person-group>
<article-title>Decreased corticolimbic allopregnanolone
expression during social isolation enhances contextual fear: A model
relevant for posttraumatic stress disorder</article-title>. <source/>Proc
Natl Acad Sci
<year>2008</year>; <volume>105</volume>:
<fpage>5567</fpage>–<lpage>5572</lpage>.<pub-id pub-id-type="pmid">18391192</pub-id></mixed-citation>
</ref>
<ref id="bibr119-2470547018818555">
<label>119</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinna</surname><given-names>G</given-names></name><name><surname>Dong</surname><given-names>E</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><etal>et al.</etal></person-group>
<article-title>In socially isolated mice, the reversal of brain allopregnanolone
down-regulation mediates the anti-aggressive action of
fluoxetine</article-title>. <source/>Proc Natl Acad Sci
<year>2003</year>; <volume>100</volume>:
<fpage>2035</fpage>–<lpage>2040</lpage>.<pub-id pub-id-type="pmid">12571361</pub-id></mixed-citation>
</ref>
<ref id="bibr120-2470547018818555">
<label>120</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinna</surname><given-names>G</given-names></name><name><surname>Rasmusson</surname><given-names>AM</given-names></name></person-group>
<article-title>Up-regulation of neurosteroid biosynthesis as a
pharmacological strategy to improve behavioural deficits in a putative mouse
model of post-traumatic stress disorder</article-title>. <source/>J
Neuroendocrinol
<year>2012</year>; <volume>24</volume>:
<fpage>102</fpage>–<lpage>116</lpage>.<pub-id pub-id-type="pmid">21981145</pub-id></mixed-citation>
</ref>
<ref id="bibr121-2470547018818555">
<label>121</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L-M</given-names></name><name><surname>Qiu</surname><given-names>Z-K</given-names></name><name><surname>Zhao</surname><given-names>N</given-names></name><etal>et al.</etal></person-group>
<article-title>Anxiolytic-like effects of YL-IPA08, a potent ligand for the
translocator protein (18 kDa) in animal models of post-traumatic stress
disorder</article-title>. <source/>Int J Neuropsychopharmacol
<year>2014</year>; <volume>17</volume>(<issue>10</issue>):
<fpage>1659</fpage>–<lpage>1669</lpage>.<pub-id pub-id-type="pmid">24763106</pub-id></mixed-citation>
</ref>
<ref id="bibr122-2470547018818555">
<label>122</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locci</surname><given-names>A</given-names></name><name><surname>Pinna</surname><given-names>G</given-names></name></person-group>
<article-title>Neurosteroid biosynthesis down-regulation and
changes in GABA<sub>A</sub> receptor subunit composition: a biomarker axis
in stress-induced cognitive and emotional impairment</article-title>.
<source/>Br J Pharmacol
<year>2017</year>; <volume>74</volume>:
<fpage>3226</fpage>–<lpage>3241</lpage>.</mixed-citation>
</ref>
<ref id="bibr123-2470547018818555">
<label>123</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dichtel</surname><given-names>LE</given-names></name><name><surname>Lawson</surname><given-names>EA</given-names></name><name><surname>Schorr</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>Neuroactive steroids and affective symptoms in women across the
weight spectrum</article-title>. <source/>Neuropsychopharmacology
<year>2018</year>; <volume>43</volume>:
<fpage>1436</fpage>–<lpage>1444</lpage>.<pub-id pub-id-type="pmid">29090684</pub-id></mixed-citation>
</ref>
<ref id="bibr124-2470547018818555">
<label>124</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girdler</surname><given-names>SS</given-names></name><name><surname>Lindgren</surname><given-names>M</given-names></name><name><surname>Porcu</surname><given-names>P</given-names></name><name><surname>Rubinow</surname><given-names>DR</given-names></name><name><surname>Johnson</surname><given-names>JL</given-names></name><name><surname>Morrow</surname><given-names>AL</given-names></name></person-group>
<article-title>A history of depression in women is associated
with an altered GABAergic neuroactive steroid profile</article-title>.
<source/>Psychoneuroendocrinology
<year>2012</year>; <volume>37</volume>:
<fpage>543</fpage>–<lpage>553</lpage>.<pub-id pub-id-type="pmid">21890277</pub-id></mixed-citation>
</ref>
<ref id="bibr125-2470547018818555">
<label>125</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmusson</surname><given-names>AM</given-names></name><name><surname>Pinna</surname><given-names>G</given-names></name><name><surname>Paliwal</surname><given-names>P</given-names></name><etal>et al.</etal></person-group>
<article-title>Decreased cerebrospinal fluid allopregnanolone levels in women
with posttraumatic stress disorder</article-title>. <source/>Biol
Psychiatry
<year>2006</year>; <volume>60</volume>:
<fpage>704</fpage>–<lpage>713</lpage>.<pub-id pub-id-type="pmid">16934764</pub-id></mixed-citation>
</ref>
<ref id="bibr126-2470547018818555">
<label>126</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romeo</surname><given-names>E</given-names></name><name><surname>Strohle</surname><given-names>A</given-names></name><name><surname>Spalletta</surname><given-names>G</given-names></name><etal>et al.</etal></person-group>
<article-title>Effects of antidepressant treatment on neuroactive steroids in
major depression</article-title>. <source/>Am J Psychiatry
<year>1998</year>; <volume>155</volume>:
<fpage>910</fpage>–<lpage>913</lpage>.<pub-id pub-id-type="pmid">9659856</pub-id></mixed-citation>
</ref>
<ref id="bibr127-2470547018818555">
<label>127</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scioli-Salter</surname><given-names>E</given-names></name><name><surname>Forman</surname><given-names>DE</given-names></name><name><surname>Tun</surname><given-names>C</given-names></name><etal>et al.</etal></person-group>
<article-title>Potential neurobiological benefits of exercise in chronic pain
and posttraumatic stress disorder: pilot study</article-title>. <source/>J
Rehab Research Dev
<year>2016</year>; <volume>53</volume>:
<fpage>95</fpage>–<lpage>106</lpage>.</mixed-citation>
</ref>
<ref id="bibr128-2470547018818555">
<label>128</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strohle</surname><given-names>A</given-names></name><name><surname>Romeo</surname><given-names>E</given-names></name><name><surname>Hermann</surname><given-names>B</given-names></name><etal>et al.</etal></person-group>
<article-title>Concentrations of 3 alpha-reduced neuroactive steroids and their
precursors in plasma of patients with major depression and after clinical
recovery</article-title>. <source/>Biol Psychiatry
<year>1999</year>; <volume>45</volume>:
<fpage>274</fpage>–<lpage>277</lpage>.<pub-id pub-id-type="pmid">10023501</pub-id></mixed-citation>
</ref>
<ref id="bibr129-2470547018818555">
<label>129</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uzunova</surname><given-names>V</given-names></name><name><surname>Sheline</surname><given-names>Y</given-names></name><name><surname>Davis</surname><given-names>JM</given-names></name><etal>et al.</etal></person-group>
<article-title>Increase in the cerebrospinal fluid content of neurosteroids in
patients with unipolar major depression who are receiving fluoxetine or
fluvoxamine</article-title>. <source/>Proc Natl Acad Sci
<year>1998</year>; <volume>95</volume>:
<fpage>3239</fpage>–<lpage>3244</lpage>.<pub-id pub-id-type="pmid">9501247</pub-id></mixed-citation>
</ref>
<ref id="bibr130-2470547018818555">
<label>130</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>MI</given-names></name><name><surname>Seippel</surname><given-names>LE</given-names></name><name><surname>Purdy</surname><given-names>RH</given-names></name><etal>et al.</etal></person-group>
<article-title>Relationship between symptom severity and steroid variation in
women with premenstrual syndrome: study on serum pregnenolone, pregnenolone
sulfate, 5 alpha-pregnane-3, 20-dione and 3 alpha-hydroxy-5
alpha-pregnan-20-one</article-title>. <source/>J Clin Endocrin Metab
<year>1996</year>; <volume>81</volume>:
<fpage>1076</fpage>–<lpage>1082</lpage>.</mixed-citation>
</ref>
<ref id="bibr131-2470547018818555">
<label>131</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burczynski</surname><given-names>ME</given-names></name><name><surname>Lin</surname><given-names>HK</given-names></name><name><surname>Penning</surname><given-names>TM</given-names></name></person-group>
<article-title>Isoform-specific induction of a human aldo-keto
reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and
oxidative stress: Implications for the alternative pathway of PAH activation
catalyzed by human dihydrodiol dehydrogenase</article-title>. <source/>Cancer
Res
<year>1999</year>; <volume>59</volume>:
<fpage>607</fpage>–<lpage>614</lpage>.<pub-id pub-id-type="pmid">9973208</pub-id></mixed-citation>
</ref>
<ref id="bibr132-2470547018818555">
<label>132</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>H</given-names></name><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Ji</surname><given-names>Q</given-names></name><name><surname>Stolz</surname><given-names>A</given-names></name></person-group>
<article-title>Induction of AKR1C2 by phase II inducers:
identification of a distal consensus antioxidant response element regulated
by NRF2</article-title>. <source/>Mol Pharmacol
<year>2006</year>; <volume>69</volume>:
<fpage>1662</fpage>–<lpage>1672</lpage>.<pub-id pub-id-type="pmid">16478829</pub-id></mixed-citation>
</ref>
<ref id="bibr133-2470547018818555">
<label>133</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palackal</surname><given-names>NT</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Harvey</surname><given-names>RG</given-names></name><name><surname>Blair</surname><given-names>IA</given-names></name><name><surname>Penning</surname><given-names>TM</given-names></name></person-group>
<article-title>Activation of polycyclic aromatic hydrocarbon
trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C)
enzymes and their functional overexpression in human lung carcinoma (A549)
cells</article-title>. <source/>J Biol Chem
<year>2002</year>; <volume>277</volume>:
<fpage>24799</fpage>–<lpage>24808</lpage>.<pub-id pub-id-type="pmid">11978787</pub-id></mixed-citation>
</ref>
<ref id="bibr134-2470547018818555">
<label>134</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatliff</surname><given-names>J</given-names></name><name><surname>Campanella</surname><given-names>M</given-names></name></person-group>
<article-title>TSPO is a REDOX regulator of cell
mitophagy</article-title>. <source/>Biochem Soc Trans
<year>2015</year>; <volume>43</volume>(<issue>4</issue>):
<fpage>543</fpage>–<lpage>552</lpage>.<pub-id pub-id-type="pmid">26551691</pub-id></mixed-citation>
</ref>
<ref id="bibr135-2470547018818555">
<label>135</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yahyapour</surname><given-names>R</given-names></name><name><surname>Motevaseli</surname><given-names>E</given-names></name><name><surname>Rezaeyan</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<article-title>Reduction–oxidation (redox) system in radiation-induced normal
tissue injury: molecular mechanisms and implications in radiation
therapeutics</article-title>. <source/>Clin Transl Oncol
<year>2018</year>; <volume>20</volume>(<issue>8</issue>):
<fpage>975</fpage>–<lpage>988</lpage>.<pub-id pub-id-type="pmid">29318449</pub-id></mixed-citation>
</ref>
<ref id="bibr136-2470547018818555">
<label>136</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>KC</given-names></name><name><surname>Cui</surname><given-names>JY</given-names></name><name><surname>Klaassen</surname><given-names>CD</given-names></name></person-group>
<article-title>Effect of graded Nrf2 activation on phase-I and
-II drug metabolizing enzymes and transporters in mouse
liver</article-title>. <source/>PLoS One
<year>2012</year>; <volume>7</volume>(<issue>7</issue>):
<fpage>e39006</fpage>.<pub-id pub-id-type="pmid">22808024</pub-id></mixed-citation>
</ref>
<ref id="bibr137-2470547018818555">
<label>137</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kliewer</surname><given-names>SA</given-names></name><name><surname>Goodwin</surname><given-names>B</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name></person-group>
<article-title>The nuclear pregnane X receptor: a key regulator
of xenobiotic metabolism</article-title>. <source/>Endocr Rev
<year>2002</year>; <volume>23</volume>:
<fpage>687</fpage>–<lpage>702</lpage>.<pub-id pub-id-type="pmid">12372848</pub-id></mixed-citation>
</ref>
<ref id="bibr138-2470547018818555">
<label>138</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frye</surname><given-names>CA</given-names></name><name><surname>Koonce</surname><given-names>CJ</given-names></name><name><surname>Walf</surname><given-names>AA</given-names></name></person-group>
<article-title>The pregnane xenobiotic receptor, a prominent
liver factor, has actions in the midbrain for neurosteroid synthesis and
behavioral/neural plasticity of female rats</article-title>. <source/>Front
Syst Neurosci
<year>2014</year>; <volume>8</volume>: <fpage>60</fpage>.<pub-id pub-id-type="pmid">24795576</pub-id></mixed-citation>
</ref>
<ref id="bibr139-2470547018818555">
<label>139</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laue</surname><given-names>L</given-names></name><name><surname>Hoeg</surname><given-names>JM</given-names></name><name><surname>Barnes</surname><given-names>K</given-names></name><name><surname>Loriaux</surname><given-names>DL</given-names></name><name><surname>Chrousos</surname><given-names>GP</given-names></name></person-group>
<article-title>The effect of mevinolin on steroidogenesis in
patients with defects in the low density lipoprotein receptor
pathway</article-title>. <source/>J Clin Endocrinol Metab
<year>1987</year>; <volume>64</volume>:
<fpage>531</fpage>–<lpage>535</lpage>.<pub-id pub-id-type="pmid">3029155</pub-id></mixed-citation>
</ref>
<ref id="bibr140-2470547018818555">
<label>140</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braamskamp</surname><given-names>MJAM</given-names></name><name><surname>Kusters</surname><given-names>DM</given-names></name><name><surname>Wiegman</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>
<article-title>Gonadal steroids, gonadotropins and DHEAS in young adults with
familial hypercholesterolemia who had initiated statin therapy in
childhood</article-title>. <source/>Atherosclerosis
<year>2015</year>; <volume>241</volume>(<issue>2</issue>):
<fpage>427</fpage>–<lpage>432</lpage>.<pub-id pub-id-type="pmid">26079405</pub-id></mixed-citation>
</ref>
<ref id="bibr141-2470547018818555">
<label>141</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hyyppä</surname><given-names>MT</given-names></name><name><surname>Kronholm</surname><given-names>E</given-names></name><name><surname>Virtanen</surname><given-names>A</given-names></name><name><surname>Leino</surname><given-names>A</given-names></name><name><surname>Jula</surname><given-names>A</given-names></name></person-group>
<article-title>Does simvastatin affect mood and steroid hormone
levels in hypercholesterolemic men? A randomized double-blind
trial</article-title>. <source/>Psychoneuroendocrinology
<year>2003</year>; <volume>28</volume>(<issue>2</issue>):
<fpage>181</fpage>–<lpage>194</lpage>.<pub-id pub-id-type="pmid">12510011</pub-id></mixed-citation>
</ref>
<ref id="bibr142-2470547018818555">
<label>142</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>WL</given-names></name><name><surname>Auchus</surname><given-names>RJ</given-names></name></person-group>
<article-title>The molecular biology, biochemistry, and
physiology of human steroidogenesis and its disorders</article-title>.
<source/>Endocr Rev
<year>2011</year>; <volume>32</volume>(<issue>1</issue>):
<fpage>81</fpage>–<lpage>151</lpage>.<pub-id pub-id-type="pmid">21051590</pub-id></mixed-citation>
</ref>
<ref id="bibr143-2470547018818555">
<label>143</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>NG</given-names></name><name><surname>Mo</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Garippa</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>S-F</given-names></name></person-group>
<article-title>Hormonal pathways regulating intermale and
interfemale aggression</article-title>. <source/>Int Rev Neurobiol
<year>2006</year>; <volume>73</volume>:
<fpage>99</fpage>–<lpage>123</lpage>.<pub-id pub-id-type="pmid">16737902</pub-id></mixed-citation>
</ref>
<ref id="bibr144-2470547018818555">
<label>144</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imperato-McGinley</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>YS</given-names></name></person-group>
<article-title>Androgens and male physiology the syndrome of
5α-reductase-2 deficiency</article-title>. <source/>Mol Cell
Endocrinol
<year>2002</year>; <volume>198</volume>(<issue>1–2</issue>):
<fpage>51</fpage>–<lpage>59</lpage>.<pub-id pub-id-type="pmid">12573814</pub-id></mixed-citation>
</ref>
<ref id="bibr145-2470547018818555">
<label>145</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillespie</surname><given-names>CF</given-names></name><name><surname>Almli</surname><given-names>LM</given-names></name><name><surname>Smith</surname><given-names>AK</given-names></name><etal>et al.</etal></person-group>
<article-title>Sex dependent influence of a functional polymorphism in steroid
5-α-reductase type 2 (SRD5A2) on post-traumatic stress
symptoms</article-title>. <source/>Am J Med Genet Part B Neuropsychiatr
Genet
<year>2013</year>; <volume>162</volume>(<issue>3</issue>):
<fpage>283</fpage>–<lpage>292</lpage>.</mixed-citation>
</ref>
<ref id="bibr146-2470547018818555">
<label>146</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanchuck-Nipper</surname><given-names>MA</given-names></name><name><surname>Ford</surname><given-names>MM</given-names></name><name><surname>Hertzberg</surname><given-names>A</given-names></name><name><surname>Beadles-Bohling</surname><given-names>A</given-names></name><name><surname>Cozzoli</surname><given-names>DK</given-names></name><name><surname>Finn</surname><given-names>DA</given-names></name></person-group>
<article-title>Sex differences in ethanol’s anxiolytic effect
and chronic ethanol withdrawal severity in mice with a null mutation of the
5α-reductase type 1 gene</article-title>. <source/>Behav Genet
<year>2015</year>; <volume>45</volume>(<issue>3</issue>):
<fpage>354</fpage>–<lpage>367</lpage>.<pub-id pub-id-type="pmid">25355320</pub-id></mixed-citation>
</ref>
<ref id="bibr147-2470547018818555">
<label>147</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Fan</surname><given-names>D-D</given-names></name><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Xing</surname><given-names>N-Z</given-names></name><name><surname>Niu</surname><given-names>Y-N</given-names></name></person-group>
<article-title>Differential expression of 5-alpha reductase
isozymes in the prostate and its clinical implications</article-title>.
<source/>Asian J Androl
<year>2014</year>; <volume>16</volume>(<issue>2</issue>):
<fpage>274</fpage>–<lpage>279</lpage>.<pub-id pub-id-type="pmid">24457841</pub-id></mixed-citation>
</ref>
<ref id="bibr148-2470547018818555">
<label>148</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caruso</surname><given-names>D</given-names></name><name><surname>Abbiati</surname><given-names>F</given-names></name><name><surname>Giatti</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>Patients treated for male pattern hair with finasteride show,
after discontinuation of the drug, altered levels of neuroactive steroids in
cerebrospinal fluid and plasma</article-title>. <source/>J Steroid Biochem
Mol Biol
<year>2015</year>; <volume>146</volume>:
<fpage>74</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">24717976</pub-id></mixed-citation>
</ref>
<ref id="bibr149-2470547018818555">
<label>149</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melcangi</surname><given-names>RC</given-names></name><name><surname>Santi</surname><given-names>D</given-names></name><name><surname>Spezzano</surname><given-names>R</given-names></name><etal>et al.</etal></person-group>
<article-title>Neuroactive steroid levels and psychiatric and andrological
features in post-finasteride patients</article-title>. <source/>J Steroid
Biochem Mol Biol
<year>2017</year>; <volume>171</volume>:
<fpage>229</fpage>–<lpage>235</lpage>.<pub-id pub-id-type="pmid">28408350</pub-id></mixed-citation>
</ref>
<ref id="bibr150-2470547018818555">
<label>150</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>Q</given-names></name><name><surname>Aoyama</surname><given-names>C</given-names></name><name><surname>Nien</surname><given-names>Y-D</given-names></name><etal>et al.</etal></person-group>
<article-title>Selective loss of AKR1C1 and AKR1C2 in breast cancer and their
potential effect on progesterone signaling</article-title>. <source/>Cancer
Res
<year>2004</year>; <volume>64</volume>(<issue>20</issue>):
<fpage>7610</fpage>–<lpage>7617</lpage>.<pub-id pub-id-type="pmid">15492289</pub-id></mixed-citation>
</ref>
<ref id="bibr151-2470547018818555">
<label>151</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>Q</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>VanDenBerg</surname><given-names>D</given-names></name><name><surname>Stanczyk</surname><given-names>FZ</given-names></name><name><surname>Stolz</surname><given-names>A</given-names></name></person-group>
<article-title>Selective reduction of AKR1C2 in prostate cancer
and its role in DHT metabolism</article-title>. <source/>Prostate
<year>2003</year>; <volume>54</volume>(<issue>4</issue>):
<fpage>275</fpage>–<lpage>289</lpage>.<pub-id pub-id-type="pmid">12539226</pub-id></mixed-citation>
</ref>
<ref id="bibr152-2470547018818555">
<label>152</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>AZ</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Ji</surname><given-names>Q</given-names></name><etal>et al.</etal></person-group>
<article-title>A Novel Mechanism for Hirsutism</article-title>. <source/>In
Vivo
<year>2008</year>; <volume>93</volume>:
<fpage>1298</fpage>–<lpage>1303</lpage>.</mixed-citation>
</ref>
<ref id="bibr153-2470547018818555">
<label>153</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>ZK</given-names></name><name><surname>Zhang</surname><given-names>LM</given-names></name><name><surname>Zhao</surname><given-names>N</given-names></name><etal>et al.</etal></person-group>
<article-title>Repeated administration of AC-5216, a ligand for the 18 kDa
translocator protein, improves behavioral deficits in a mouse model of
post-traumatic stress disorder</article-title>. <source/>Prog
Neuro-Psychopharmacology Biol Psychiatry
<year>2013</year>; <volume>45</volume>:
<fpage>40</fpage>–<lpage>46</lpage>.</mixed-citation>
</ref>
<ref id="bibr154-2470547018818555">
<label>154</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rupprecht</surname><given-names>R</given-names></name><name><surname>Papadopoulos</surname><given-names>V</given-names></name><name><surname>Rammes</surname><given-names>G</given-names></name><etal>et al.</etal></person-group>
<article-title>Translocator protein (18 kDa) (TSPO) as a therapeutic target for
neurological and psychiatric disorders</article-title>. <source/>Nat Rev Drug
Discov
<year>2010</year>; <volume>9</volume>(<issue>12</issue>):
<fpage>971</fpage>–<lpage>988</lpage>.<pub-id pub-id-type="pmid">21119734</pub-id></mixed-citation>
</ref>
<ref id="bibr155-2470547018818555">
<label>155</label>
<mixed-citation publication-type="other"><comment>Zhang L-M, Qiu Z-K, Chen X-F,
et al. Involvement of allopregnanolone in the anti-PTSD-like effects of
AC-5216. <italic>J Psychopharmacol</italic>. 2016. <ext-link ext-link-type="uri" xlink:href="http://jop.sagepub.com/cgi/doi/10.1177/0269881115625115">http://jop.sagepub.com/cgi/doi/10.1177/0269881115625115</ext-link>.
Accessed November 26, 2018</comment>.</mixed-citation>
</ref>
<ref id="bibr156-2470547018818555">
<label>156</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>LM</given-names></name><name><surname>Qiu</surname><given-names>ZK</given-names></name><name><surname>Zhao</surname><given-names>N</given-names></name><etal>et al.</etal></person-group>
<article-title>Anxiolytic-like effects of YL-IPA08, a potent ligand for the
translocator protein (18 kDa) in animal models of post-traumatic stress
disorder</article-title>. <source/>Int J Neuropsychopharmacol
<year>2014</year>; <volume>29</volume>(<issue>4</issue>):
<fpage>1659</fpage>–<lpage>1669</lpage>.</mixed-citation>
</ref>
<ref id="bibr157-2470547018818555">
<label>157</label>
<mixed-citation publication-type="other"><comment>Guilarte TR. TSPO in diverse CNS
pathologies and psychiatric disease: A critical review and a way forward
[published online ahead of print September 4, 2018]. <italic>Pharmacol
Ther</italic>. 2018.
doi:10.1016/j.pharmthera.2018.09.003</comment>.</mixed-citation>
</ref>
<ref id="bibr158-2470547018818555">
<label>158</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>LD</given-names></name><name><surname>Mellon</surname><given-names>SH</given-names></name></person-group>
<article-title>Selective serotonin reuptake inhibitors directly
alter activity of neurosteroidogenic enzymes</article-title>. <source/>Proc
Natl Acad Sci
<year>1999</year>; <volume>96</volume>(<issue>23</issue>):
<fpage>13512</fpage>–<lpage>13517</lpage>.<pub-id pub-id-type="pmid">10557352</pub-id></mixed-citation>
</ref>
<ref id="bibr159-2470547018818555">
<label>159</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fry</surname><given-names>JP</given-names></name><name><surname>Li</surname><given-names>KY</given-names></name><name><surname>Devall</surname><given-names>AJ</given-names></name><name><surname>Cockcroft</surname><given-names>S</given-names></name><name><surname>Honour</surname><given-names>JW</given-names></name><name><surname>Lovick</surname><given-names>TA</given-names></name></person-group>
<article-title>Fluoxetine elevates allopregnanolone in female
rat brain but inhibits a steroid microsomal dehydrogenase rather than
activating an aldo-keto reductase</article-title>. <source/>Br J
Pharmacol
<year>2014</year>; <volume>171</volume>(<issue>24</issue>):
<fpage>5870</fpage>–<lpage>5880</lpage>.<pub-id pub-id-type="pmid">25161074</pub-id></mixed-citation>
</ref>
<ref id="bibr160-2470547018818555">
<label>160</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bäckström</surname><given-names>T</given-names></name><name><surname>Haage</surname><given-names>D</given-names></name><name><surname>Löfgren</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>Paradoxical effects of GABA-A modulators may explain sex steroid
induced negative mood symptoms in some persons</article-title>.
<source/>Neuroscience
<year>2011</year>; <volume>191</volume>:
<fpage>46</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">21600269</pub-id></mixed-citation>
</ref>
<ref id="bibr161-2470547018818555">
<label>161</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labombarda</surname><given-names>F</given-names></name><name><surname>Ghoumari</surname><given-names>AM</given-names></name><name><surname>Liere</surname><given-names>P</given-names></name><name><surname>De Nicola</surname><given-names>AF</given-names></name><name><surname>Schumacher</surname><given-names>M</given-names></name><name><surname>Guennoun</surname><given-names>R</given-names></name></person-group>
<article-title>Neuroprotection by steroids after neurotrauma in
organotypic spinal cord cultures: A key role for progesterone receptors and
steroidal modulators of GABAA receptors</article-title>.
<source/>Neuropharmacology
<year>2013</year>; <volume>71</volume>:
<fpage>46</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">23542439</pub-id></mixed-citation>
</ref>
<ref id="bibr162-2470547018818555">
<label>162</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patte-Mensah</surname><given-names>C</given-names></name><name><surname>Meyer</surname><given-names>L</given-names></name><name><surname>Taleb</surname><given-names>O</given-names></name><name><surname>Mensah-Nyagan</surname><given-names>AG</given-names></name></person-group>
<article-title>Potential role of allopregnanolone for a safe
and effective therapy of neuropathic pain</article-title>. <source/>Prog
Neurobiol
<year>2014</year>; <volume>113</volume>:
<fpage>70</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="pmid">23948490</pub-id></mixed-citation>
</ref>
<ref id="bibr163-2470547018818555">
<label>163</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmusson</surname><given-names>AMPG</given-names></name></person-group>
<article-title>Ganaxolone improves behavioral deficits in a
mouse model of post-traumatic stress disorder</article-title>. <source/>Front
Cell Neurosci
<year>2014</year>; <volume>8</volume>: <fpage>256</fpage>.<pub-id pub-id-type="pmid">25309317</pub-id></mixed-citation>
</ref>
<ref id="bibr164-2470547018818555">
<label>164</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazdoba</surname><given-names>TM</given-names></name><name><surname>Hagerman</surname><given-names>RJ</given-names></name><name><surname>Zolkowska</surname><given-names>D</given-names></name><name><surname>Rogawski</surname><given-names>MA</given-names></name><name><surname>Crawley</surname><given-names>JN</given-names></name></person-group>
<article-title>Evaluation of the neuroactive steroid ganaxolone
on social and repetitive behaviors in the BTBR mouse model of
autism</article-title>. <source/>Psychopharmacology
<year>2016</year>; <volume>233</volume>(<issue>2</issue>):
<fpage>309</fpage>–<lpage>323</lpage>.<pub-id pub-id-type="pmid">26525567</pub-id></mixed-citation>
</ref>
<ref id="bibr165-2470547018818555">
<label>165</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milivojevic</surname><given-names>V</given-names></name><name><surname>Fox</surname><given-names>HC</given-names></name><name><surname>Sofuoglu</surname><given-names>M</given-names></name><name><surname>Covault</surname><given-names>J</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name></person-group>
<article-title>Effects of progesterone stimulated
allopregnanolone on craving and stress response in cocaine dependent men and
women</article-title>. <source/>Psychoneuroendocrinology
<year>2016</year>; <volume>65</volume>:
<fpage>44</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">26716877</pub-id></mixed-citation>
</ref>
<ref id="bibr166-2470547018818555">
<label>166</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaccara</surname><given-names>G</given-names></name><name><surname>Schmidt</surname><given-names>D</given-names></name></person-group>
<article-title>Do traditional anti-seizure drugs have a future?
A review of potential anti-seizure drugs in clinical
development</article-title>. <source/>Pharmacol Res
<year>2016</year>; <volume>104</volume>:
<fpage>38</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">26689774</pub-id></mixed-citation>
</ref>
<ref id="bibr167-2470547018818555">
<label>167</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmusson</surname><given-names>AM</given-names></name><name><surname>Marx</surname><given-names>CE</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>A randomized controlled trial of ganaxolone in posttraumatic
stress disorder</article-title>. <source/>Psychopharmacology
<year>2017</year>; <volume>234</volume>(<issue>15</issue>):
<fpage>2245</fpage>–<lpage>2257</lpage>.<pub-id pub-id-type="pmid">28667510</pub-id></mixed-citation>
</ref>
<ref id="bibr168-2470547018818555">
<label>168</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengtsson</surname><given-names>SK</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Bäckström</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name></person-group>
<article-title>Chronic allopregnanolone treatment accelerates
alzheimer’s disease development in AβPPSwePSEN1ΔE9mice</article-title>.
<source/>J Alzheimer’s Dis
<year>2012</year>; <volume>31</volume>(<issue>1</issue>):
<fpage>71</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">22495347</pub-id></mixed-citation>
</ref>
<ref id="bibr169-2470547018818555">
<label>169</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbaccia</surname><given-names>M</given-names></name><name><surname>Serra</surname><given-names>M</given-names></name><name><surname>Purdy</surname><given-names>R</given-names></name><name><surname>Biggio</surname><given-names>G</given-names></name></person-group>
<article-title>Stress and neuroactive steroids</article-title>.
<source/>Int Rev Neurobiol
<year>2001</year>; <volume>46</volume>:
<fpage>243</fpage>–<lpage>272</lpage>.<pub-id pub-id-type="pmid">11599302</pub-id></mixed-citation>
</ref>
<ref id="bibr170-2470547018818555">
<label>170</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantarero</surname><given-names>G</given-names></name><name><surname>Tang</surname><given-names>B</given-names></name><name><surname>O’Malley</surname><given-names>R</given-names></name><name><surname>Salas</surname><given-names>R</given-names></name><name><surname>Celnik</surname><given-names>P</given-names></name></person-group>
<article-title>Motor Learning Interference Is Proportional to
Occlusion of LTP-Like Plasticity</article-title>. <source/>J
Neurosci
<year>2013</year>; <volume>33</volume>(<issue>11</issue>):
<fpage>4634</fpage>–<lpage>4641</lpage>.<pub-id pub-id-type="pmid">23486938</pub-id></mixed-citation>
</ref>
<ref id="bibr171-2470547018818555">
<label>171</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>IM</given-names></name><name><surname>Birzniece</surname><given-names>V</given-names></name><name><surname>Lindblad</surname><given-names>C</given-names></name><name><surname>Olsson</surname><given-names>T</given-names></name><name><surname>Bäckström</surname><given-names>T</given-names></name></person-group>
<article-title>Allopregnanolone inhibits learning in the Morris
water maze</article-title>. <source/>Brain Res
<year>2002</year>; <volume>934</volume>(<issue>2</issue>):
<fpage>125</fpage>–<lpage>131</lpage>.<pub-id pub-id-type="pmid">11955475</pub-id></mixed-citation>
</ref>
<ref id="bibr172-2470547018818555">
<label>172</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundgren</surname><given-names>P</given-names></name><name><surname>Strömberg</surname><given-names>J</given-names></name><name><surname>Bäckström</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name></person-group>
<article-title>Allopregnanolone-stimulated GABA-mediated
chloride ion flux is inhibited by 3β-hydroxy-5α-pregnan-20-one
(isoallopregnanolone)</article-title>. <source/>Brain Res
<year>2003</year>; <volume>982</volume>(<issue>1</issue>):
<fpage>45</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">12915239</pub-id></mixed-citation>
</ref>
<ref id="bibr173-2470547018818555">
<label>173</label>
<mixed-citation publication-type="other"><comment>Öfverman C, Strömberg J, Birzniece
V, Turkmen S. The progesterone metabolite isoallopregnanolone is a
subunit-selective antagonist of the GABA-A receptor. <italic>Digit
Vetenskapliga Ark</italic>. 2009. <ext-link ext-link-type="uri" xlink:href="http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-27069">http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-27069</ext-link>.
Accessed November 26, 2018</comment>.</mixed-citation>
</ref>
<ref id="bibr174-2470547018818555">
<label>174</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bäckström</surname><given-names>T</given-names></name><name><surname>Wahlström</surname><given-names>G</given-names></name><name><surname>Wahlström</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>M De</given-names></name></person-group>
<article-title>Isoallopregnanolone; an antagonist to the
anaesthetic effect of allopregnanolone in male rats</article-title>.
<source/>Eur J Pharmacol
<year>2005</year>; <volume>512</volume>(<issue>1</issue>):
<fpage>15</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">15814085</pub-id></mixed-citation>
</ref>
<ref id="bibr175-2470547018818555">
<label>175</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bengtsson</surname><given-names>SKS</given-names></name><name><surname>Nyberg</surname><given-names>S</given-names></name><name><surname>Hedström</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<article-title>Isoallopregnanolone antagonize allopregnanolone-induced effects
on saccadic eye velocity and self-reported sedation in
humans</article-title>. <source/>Psychoneuroendocrinology
<year>2015</year>; <volume>52</volume>(<issue>1</issue>):
<fpage>22</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">25459890</pub-id></mixed-citation>
</ref>
<ref id="bibr176-2470547018818555">
<label>176</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park-Chung</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>FS</given-names></name><name><surname>Purdy</surname><given-names>RH</given-names></name><name><surname>Malayev</surname><given-names>AA</given-names></name><name><surname>Gibbs</surname><given-names>TT</given-names></name><name><surname>Farb</surname><given-names>DH</given-names></name></person-group>
<article-title>Distinct sites for inverse modulation of
N-methyl-D-aspartate receptors by sulfated steroids</article-title>.
<source/>Mol Pharmacol
<year>1997</year>; <volume>52</volume>(<issue>6</issue>):
<fpage>1113</fpage>–<lpage>1123</lpage>.<pub-id pub-id-type="pmid">9396781</pub-id></mixed-citation>
</ref>
<ref id="bibr177-2470547018818555">
<label>177</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibbs</surname><given-names>TT</given-names></name><name><surname>Russek</surname><given-names>SJ</given-names></name><name><surname>Farb</surname><given-names>DH</given-names></name></person-group>
<article-title>Sulfated steroids as endogenous
neuromodulators</article-title>. <source/>Pharmacol Biochem Behav
<year>2006</year>; <volume>84</volume>(<issue>4</issue>):
<fpage>555</fpage>–<lpage>567</lpage>.<pub-id pub-id-type="pmid">17023038</pub-id></mixed-citation>
</ref>
<ref id="bibr178-2470547018818555">
<label>178</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rupprecht</surname><given-names>R</given-names></name><name><surname>Di Michele</surname><given-names>F</given-names></name><name><surname>Hermann</surname><given-names>B</given-names></name><etal>et al.</etal></person-group>
<article-title>Neuroactive steroids: Molecular mechanisms of action and
implications for neuropsychopharmacology</article-title>. <source/>Brain Res
Rev
<year>2001</year>; <volume>37</volume>(<issue>1–3</issue>):
<fpage>59</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="pmid">11744074</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>